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Abstract 
Tenofovir (TFV) and emtricitabine (FTC) are nucleoside reverse transcriptase inhibitors, often used in pre-
exposure prophylaxis (PrEP) trials: where antiretroviral drugs are administered to high-risk, HIV-negative 
individuals to prevent HIV infection. Both drugs are safe when taken either daily or intermittently, which is ideal for 
PrEP regimens where adherence may not be high. The minimum number of doses estimated to confer high PrEP 
efficacy for a TFV/FTC regimen is four or more doses per week, resulting in a 95% lower risk of HIV acquisition. 
However, this is highly dependent on various host factors, of which adherence plays the largest role.  
The aim of the project was to develop a novel sensitive, specific, and robust direct method for the measurement 
of adherence, utilising tenofovir-diphosphate (TFV-DP) in dry blood spots (DBS) through LC-MS/MS analysis, to 
replace the current costly and laborious indirect method currently used to elucidate adherence of patients. This 
indirect method faces challenges, due to the polar nature of TFV and its metabolites, leading to separation and 
retention issues. The existing method applied a technique which separated the parent drug from the metabolite 
and then back-converted all metabolites to the parent drug before analysing the samples on LC-MS/MS. The 
developed alternative method aimed to reduce the time taken for each assay and the associated cost of 
consumables.  
TFV-DP is a highly polar compound and traditional reverse-phase chromatography has poor retention and 
separation capabilities when used to retain polar compounds, therefore alternative strategies were implemented. 
In this developed direct method, an anion exchange column was used along with a pH gradient, with the aim of 
improving separation and chromatography of TFV, TFV-DP, and tenofovir-monophosphate (TFV-MP). The method 
was optimised and validated using current U.S. Food and Drug Administration (FDA) and European Medical 
Agency (EMA) guidelines. The use of the anion exchange column resulted in a marked increase in retention time 
and allowed baseline separation of TFV, TFV-DP, and TFV-MP.  
Determination of TFV-DP from DBS was performed using three 3 mm DBS punches per sample, which underwent 
an extraction procedure followed by high-performance liquid chromatography with tandem mass spectrometry 
detection on an AB Sciex Qtrap 5500 mass spectrometer. The transitions of the protonated precursor ions were 
monitored at m/z 448.0 and 452.9 to the product ions m/z 350.0 and 354.9 for TFV-DP and the deuterated TFV-
DP internal standard, respectively. The method was validated over a range of 50–6400 fmol/punch for TFV-DP. 
The developed direct method had a lower limit of quantification (LLOQ) of 50 fmol/punch, which was higher than 
that of the indirect method; therefore, it had less sensitivity. The reduced sensitivity was acceptable, since the 
methods were meant for the measurement of adherence. The direct method had an ULOQ of 6400 fmol/punch, 
which was similar to that of the indirect method. The direct method also required significantly less on-bench sample 
processing and, therefore, was less time consuming and costly. To determine the suitability and accuracy of the 
direct method in comparison to the indirect method a comparative analysis was completed by analysing the same 
samples using both the indirect and direct method. The developed method met all the validation requirements and 
a strong correlation was observed between the results of the indirect and direct methods during the comparative 
analysis. 
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Chapter 1: Introduction 
 
An estimated.two-thirds of the 36.7 million people infected with.the Human immunodeficiency.virus (HIV), reside 
on the African.continent 1. Once infection.has occurred, HIV destroys.the hosts CD4+ immune.cells, leading to 
acquired.immunodeficiency syndrome (AIDS) 2. .HIV/AIDS is wide.spread throughout.Sub-Saharan Africa and 
exacerbates various.socioeconomic issues 3. South Africa has.some of the highest prevalence.of HIV/AIDS.in the 
world, with an.estimated 7 million people.living with HIV 4. .An estimated 115 000.HIV-related deaths occurred in 
South Africa in 2018, .emphasizing the.need for HIV research.in Sub-Saharan.countries 4.  
1.1. Human Immunodeficiency Virus-1 and Virus Cycle 
The HIV-1 virus.consists of two copies.of non-covalently.linked, positive.sense, single-stranded.RNA molecules 5. 
This is enclosed.by a p24 viral.protein.conical capsid, situated.within a.viral envelope. .The viral envelope is 
derived from the.host cell membrane and.contains viral.glycoproteins; such.as gp120.and gp41, which.are 
imbedded.in the viral.envelope 2,6,7. .Once HIV-1 exposure.occurs, .the virus migrates.to CD4+ immune.cells. This 
occurs.due to the.affinity of the HIV-1 viral.envelope.gp120/gp41 complex.for CD4 antigen.receptors on the 
surface of host.CD4+ immune cells 2,6. Once.the gp120 subunit.of the viral envelope.interacts with a CD.antigen 
receptor, co-receptor binding.takes place 2,7. The co-receptor.binding results in conformation.changes in the HIV-
1 envelope, .leading to the exposure.of the gp41 hydrophobic.domain, allowing.fusion of the.envelope with.the 
cellular.membrane and the.subsequent delivery.of the viral core.into the cytoplasm 2. The.uncoating of the.viral 
core exposes.Reverse transcriptase, a HIV.enzyme, to deoxynucleotide.triphosphates (dNTP’s), resulting in 
reverse transcription.and proviral DNA synthesis 2. After reverse.transcription is completed, .the formation.of a 
complex, consisting of.viral and cellular components is.formed, known as the viral pre-integration.complex. This is 
transported to the.cell’s nucleus where the.HIV-1 enzyme, Integrase, catalyses.the integration of the viral.genome 
with the human.DNA 2,7. This maintains the.viral DNA.in the infected host cell and allows.transcription, thus the 
cell can express viral.mRNA and viral RNA. Once.transcription is initiated, the necessary viral.constituents move 
to the inside of the plasma.membrane and assemble to form an.immature HIV-1 virus 2. The newly.formed 
immature virus buds.off from the cell and releases.protease to break down large.HIV-1 protein chains. .These 
broken down HIV protein.chains, combine to form.a mature HIV-1 virus 2.  
 
The viral life.cycle, discussed above (shown in Figure 1.1), can be.subdivided into seven.distinct stages, namely 
binding; fusion; reverse.transcription; integration; replication; .virus assembly/production; and.budding. The HIV-1 
lifecyclexpresents various.potential opportunities for.therapeutic intervention.and six distinctclasses of 
antiretrovirals (ARVs) havexbeen developed 2. 
 
 14 
 
 
Figure 1.1: Each of the sevenxstages of the HIV-1 virus life cycle is shownxabove. The targeted sitesxfor different 
classes of ARVs, arexalso shown 8. 
 
1.2. Classes of Antiretrovirals  
Each of thexdifferent ARV classes target a specificxstage in the HIV-1 life cycle and can bexsubdivided as follows: 
nucleoside reverse transcriptasexinhibitors (NRTIs), non-nucleosidexreverse transcriptasexinhibitors (NNRTIs), 
protease inhibitors (PIs), fusion inhibitors, integrasexinhibitors, and co-receptor antagonists 2. All the ARVxclasses, 
except co-receptorxantagonists, are currently available inxSouthern Africa 9. The most commonlyxused ARVs are 
NRTIs and NNRTIs and thesexaccount for half of allxapproved ARVs 2. The 2017 Adult SouthxAfrican antiretroviral 
guidelinesxandxWorld Health Organisation (WHO) recommend axregimen consisting of two NRTIs, co-
administered with axNNRTI 9,10. 
NRTIs are a class of ARVs used in the treatment and prevention of viral infections such as HIV; hepatitis viruses 
B and C; and the Human Herpes viruses. NRTIs target reverse transcription (Figure 1.1). These compounds are 
activated by phosphorylation carried out by cellular enzymes 7,11–13. Once phosphorylation has occurred these 
compounds become analogues of the naturally occurring deoxynucleotides needed to synthesize viral DNA. NRTIs 
metabolites compete with the natural deoxynucleotides for incorporation into viral DNA during reverse transcription 
7. The NRTIs lack a 3′-hydroxyl group on the deoxyribose moiety, which is needed for binding of new 
deoxynucleotides, implying that the next 5′–3′ phosphodiester bond necessary to extend the DNA chain cannot 
form, resulting in viral DNA chain termination and the termination of viral replication within the host 8 (Figure 1.2). 
Proper treatment with NRTIs can prevent HIV infection and results in the suppression of the viral plasma levels 
below the limit of detection. This leads to an increase in the number of CD4+ lymphocyte cells and is accompanied 
by the restoration of pathogen-specific immune function in HIV-1 infected patients. This subsequently leads to a 
significant decreases in HIV-associated morbidity and mortality 9,11,14–17. 
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1.3.  Nucleoside Reverse Transcriptase Inhibitors in vivo 
The chronic administration of NRTIs may lead to various adverse effects, due to the affinity of NRTIs for human 
DNA-polymerases, other than Reverse transcriptase 18. Mitochondrial toxicity is considered as the most significant 
adverse effect of NRTIs. Other adverse effects include, myopathy, peripheral neuropathy, and hepatic steatosis 
with lactic acidosis, which can all be lethal conditions 18. Toxicity can be decreased by optimising dosages and the 
use of drug regimens with high potency, good safety profiles and limited drug interactions. Low toxicity levels are 
paramount for both HIV patient treatment and pre-exposure prophylaxis (PrEP) regimens 11,19. In PrEP regimens, 
antiretroviral drugs are administered to high-risk HIV-negative individuals, with the aim of preventing HIV infection 
should exposure occur 12,19,20.  
The preferred HIV-1 first-line treatment is selected based on the antiretroviral therapy (ART)  exhibiting favourable 
characteristics such as decreased toxicity; minimum drug-drug interactions; and increased simplicity and 
convenience 21. Fixed-dose combinations (FDCs) allow once-daily regimens and any ART that can be prescribed 
in a FDC format is preferred due to its simplicity 10. As stated earlier, according to the WHO guidelines, ART should 
consist of two NRTI and a NNRTI 10. The recommended NRTI in first-line treatment consists of once-daily 
combinations of tenofovir disoproxil fumarate (TDF) with emtricitabine (FTC) or Lamivudine (3TC) 9. Currently 
Efavirenz (EFV) is recommended as the preferred  NNRTI co-administered in the first-line treatment 10.  The 
simplicity of once-daily regimens should help improve patient adherence. Truvada® was approved by the U.S. 
Food and Drug Administration (FDA) in 2012 and consists of TDF co-administered with FTC 22. TDF is an oral 
prodrug of tenofovir (TFV) and requires initial diester hydrolysis to form TFV, which is an adenine-5′-
monophosphate analogue 23. Once absorbed, TFV is phosphorylated within the cell to the intermediate metabolite, 
tenofovir-monophosphate (TFV-MP), and ultimately, to the more abundant pharmacologically active metabolite, 
tenofovir-diphosphate (TFV-DP) 24. It is often used in PrEP studies and has been shown to be effective in HIV 
treatment and prevention, although the efficacy is highly dependent on adherence 12.  
Studies have demonstrated that TDF, in combination with FTC regimens, are safe when taken either daily or 
intermittently, which is ideal for PrEP, where adherence may not be as high. The minimum number of doses 
estimated to confer high PrEP efficacy for a TDF/FTC regimen is four or more per week, resulting in a 95% lower 
risk of HIV acquisition 19,25,26. Adherence levels between 70–95% have been associated with clinical benefit in HIV 
patients, although higher levels are necessary for sustained viral suppression and the prevention of drug-resistant 
HIV-1 strains 27,28. 
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Figure 1.2: NRTIs mode of action. NRTIs act as competitive inhibitors of reverse transcriptase inhibitors. Adapted 
from Saayman et al. 8. 
 
1.4. Measuring Adherence to Tenofovir 
Adherence refers to the patient’s compliance with the prescribed regimen. It is defined as the degree to which a 
patient correctly follows a prescribed treatment plan and abides by the prescribed dosage frequencies and times 
29. Adherence is a concern in any chronically administered treatment and measures are required to determine 
patient compliance. A recent study determined that the average nonadherence rate for patients is around 25%, 
indicting a serious need for compliance strategies 30.  
Exact adherence measurements are often necessary for correct evaluation of therapeutic efficacy, to provide direct 
pharmacologic measures of drug exposure, since they have been shown to be paramount for trial interpretation in 
several studies 31,32. Patient adherence is also essential when considering the development of drug resistance. 
Drug-resistant mutant strains of the HIV virus arise rapidly due to the short half-life of the virus and the error-prone 
process of reverse transcription 33. These characteristics of the virus, in combination with poor adherence to ART, 
lead to HIV strains developing resistance to ARV regimens. These drug-resistant mutant strains can then be 
transmitted to drug-naïve patients leaving them with ineffective treatment options 33. 
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Various approaches have been developed as a means of measuring adherence, although self-reporting is often 
used to measure adherence in resource limited settings 29.  Self-reporting is a minimally invasive strategy and can 
easily be added to a clinical study; however, it is inaccurate and unreliable. Objective measures of patient 
compliance are far more accurate and are essential for the analysis of the efficacy of drug regimens 29. Objective 
strategies include medication event monitoring systems (MEMSs), pharmacy refill data, directly observed therapy 
(DOT), and bioanalytical approaches (pharmacologic monitoring) 34. Bioanalytical approaches include viral load 
and CD4 count, although measurement of drug concentrations in the patient’s blood is still the best assessment 
of adherence. This provides an unbiased result; however, analytes with short half-lives will only allow the 
measurement of recent drug exposure. This does not allow the measurement of long-term drug exposure and, 
therefore, it may be difficult to determine the patient’s adherence profile in its entirety 35. 
Patient adherence can be determined by utilising compounds with substantial half-life differences to measure 
recent and long-term drug exposure. This will allow the elucidation of adherence; however, this is only possible for 
compounds where the parent, and its metabolites, have significant differences in their half-lives and 
pharmacokinetic characteristics 20,24,36.  
TFV and TFV-DP are ideal candidates for this approach, since the TFV has a half-life of 15-hours and TFV-DP, 
the metabolite, has a 17-day half-life in red blood cells (RBCs). The exceptionally long half-life of TFV-DP leads 
to a 25-fold accumulation between first dose and steady state 20. Therefore, TFV-DP exhibits characteristics ideal 
for monitoring dose exposure over time in RBCs. The long half-life of TFV-DP in RBCs can also be used to smooth 
out the pharmacokinetic curve so that it represents an average drug dose over time 11. TFV has a short half-live 
(15 hours) and can be used as an indicator of recent drug exposure 20,24. Additionally, the long TFV-DP half-life 
can also be used to inform whether recent clinician dosing masks remote non-adherence and will act as a 
cumulative adherence measure which provides a better representation of a subject’s overall adherence. The long 
intracellular half-life of TFV-DP is favourable since it allows less frequent dosing; however, it could also be harmful, 
due to accumulation in higher-metabolising patients and the associated toxicity 12,37. 
The significant difference in half-life of TFV and its metabolite, thus allows the measurement of both cumulative 
and recent drug adherence. This is useful, since recent adherence measures alone may lead to misclassification 
of adherence, due to patients becoming more adherent during the days preceding clinic and study visits 35.  
The underlying principal for the measurement of adherence is the half-life of the drug. The half-life of compounds 
may differ depending on the absorbing cell type, resulting in accumulation of compounds. The half-life of TFV-DP 
in RBCs is significantly longer than those seen in peripheral blood mononuclear cells (PBMCs) (17 days and 6.25 
days respectively). Since dried blood spots (DBSs) mostly consist of RBCs, it is a suitable matrix for TFV-DP 
testing 24. DBSs offer a more versatile blood sampling method than traditional methods, this is due to the capability 
to measure both the intracellular metabolite and the parent drug 24.  
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1.5. Introduction to the Study 
TFV is recommended as the preferred first-line ART in almost all HIV-1 treatment and chemoprevention 10. This 
adds to the suitability of TFV in DBSs as a routine measure of adherence over time. Current TFV-DP quantification 
methods have various limitations relating to sensitivity, specificity and multiplex capabilities 13. Extensive sample 
preparation steps are traditionally added to concentrate the product, resulting in improved selectivity of the method 
and an increase in the sensitivity of detection. These steps are necessary, but require intensive labour and 
manipulations, thus, the need exists for an alternative method to avoid these laborious steps 38–40. The need for 
an inexpensive, simple, sensitive, and robust method for the determination of TFV and TFV-DP in DBS cannot be 
overstated, and this study serves to outline the development and validation of such a procedure. Therefore, the 
aim in the present study was to develop a sensitive, specific and robust multiplex method for the measurement of 
adherence to antiretroviral regimens, utilising TFV and TFV-DP in DBS using liquid chromatography combined 
tandem mass spectrometry (LC-MS/MS) analysis, to accomplish this, the following technical objectives were set: 
• The development of a chromatography procedure that would allow sufficient baseline separation for TFV 
and its metabolites. 
• Development of a simple and effective extraction method. 
• The validation of the method according to current FDA and EMA standards. 
• The completion of a correlation analysis, comparing results obtained from the current method and the 
newly developed method. 
This Masters’ thesis consists of six chapters, wherein the chapters will discuss each of the essential steps in the 
development and validation of this method. The introduction and background information is presented in Chapter 
1. Chapter 2, the literature review, serves to discuss and investigate previous methods and their shortfalls, and 
alternative approaches - and the hurdles that may be encountered. Chapter 3 presents the method development 
process and covers three broad areas: namely the optimisation of chromatography; the development of an 
extraction method; and optimisation of sensitivity and selectivity on the mass spectrometer. Chapter 4 summarises 
the final developed method. Chapter 5 presents the validation process according to current FDA and EMA 
guidelines. Lastly, Chapter 6 summarises the findings in the study. 
Thus far, the study produced the following outputs: 
1. An oral presentation at the 4th Annual Antivirals conference in Sitges, Barcelona, Spain, 2016. Title “The 
Development and Validation of a Direct LC-MS/MS Assay for the Determination of Tenofovir, Emtricitabine and 
their metabolites in Dried Blood Spots for the Analysis of Clinical Samples.” 
2. A Poster presentation at the Annual South African Society for Basic and Clinical Pharmacology 2017 congress 
Title: The Development and Validation of a Direct LC-MS/MS Assay for the Determination of Tenofovir and its 
metabolites in Dried Blood Spots for the Analysis of Clinical Samples.” 
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Chapter 2: Literature review 
 
Pharmacologic monitoring of TFV and TFV-DP is essential for the elucidation of adherence which allows 
evaluation of regimen efficacy and, therefore, facilitates the prevention of antiretroviral resistance and HIV-related 
mortality and morbidity. To assess adherence, an accurate and robust bioanalytical method is required. This 
section considers existing analytical methods and investigates alternative methods. 
2.1. Bioanalytical Method Development and Validation 
LC-MS/MS has become the preferred bioanalytical tool, allowing the development of simple, high precision, 
automated analytical methods with improved accuracy, sensitivity, and selectivity 41–44. Bioanalytical methods are 
used for the quantification of analytes and their metabolites in biological matrices. Such analytics play a vital role 
in the evaluation and interpretation of various studies, including bioavailability, bioequivalence, and toxicology 
studies 45. Before a bioanalytical method can be used for the analysis of biological samples, the method must 
undergo a validation process. The method must demonstrate its suitability for its intended use and ability to 
produce reliable and reproducible results, hence, regulatory entities have issued guidelines to which methods must 
adhere 41,45,46. 
Modern analytical instrumentation has led to improved selectivity and sensitivity. Of these analytical tools, LC-
MS/MS is considered as the benchmark for qualitative and quantitative analysis 41,42,44. However, limitations are 
encountered as a result of matrix effects and the associated loss of sensitivity of analytes in processed biological 
matrices 46. This is often due to the complex nature of the background molecules in these samples. Biological 
matrices are comprised of various organic components, including salts, proteins, and small organic compounds, 
like lipids 41. The choice of sampling matrix is analyte-specific and depends on various drug properties and the 
planned analytical approach. 
2.2. Sample Collection and Storage Matrix  
PBMCs are mostly used in studies with new NRTI, drug-drug interaction studies, and studies where new 
prescription strategies are developed 36. Most therapeutic drug monitoring assays are traditionally performed by 
venous blood sampling and use either serum or plasma 47. These approaches are often applied, although they are 
invasive and present various storage and transport issues. Dry blood spots (DBS) can be used as an effective 
alternative to traditional venous sampling methods and consists of whole blood, which contains erythrocytes, 
plasma, platelets, and interstitial fluid 48. DBS only requires around 50–125 µl of whole blood and recent advances 
in bioanalytical analysis have allowed the measurement of analytes in DBS, with volumes ranging between 4–12 
µl of spotted blood 49. Plasma sampling, which is the matrix of choice for pharmacodynamics and pharmacokinetic 
studies, requires more than 4 ml of blood 49. The smaller blood volumes required make DBS sampling more 
suitable for children, less invasive, and simpler in comparison to traditional venous sampling methods 47.  In 
addition to the small sampling volume, most analytes are also more stable when sampled and stored as DBS 
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cards 50. The use of DBS also simplifies the transport and storage of the samples and this is accompanied by a 
decrease in cost and labour 24,47,49,51–53. 
Capillary blood for DBS is sampled by means of a finger prick and this is usually carried out with a lancet. Patients 
will be able to perform the sampling on themselves after receiving adequate training and instruction, thus samples 
can be collected without the presence of a phlebotomist 49. After the finger prick is made, the first drop is discarded, 
due to increased tissue fluid, and the second drop is spotted onto one of the pre-marked circles on a DBS card. 
The cards are subsequently left to dry at room temperature and stored 49. Discs are punched out from the pre-
marked circle and each disk represents a fixed volume of absorbed blood 49,54.  
The logistical constraints accompanying sampling, storage and collection of traditional biological samples in 
community-based settings have significantly limited research and monitoring. Therefore, DBS is an ideal substitute 
to traditional sampling methods, since it provides a minimally invasive alternative, with simplified collection, storage 
and transport requirements; however, DBSs only provide small volumes, which require higher sensitivity in 
subsequent analysis. It also presents an issue when samples need to be reanalysed or if samples need to be used 
for more than one analysis 49. Other disadvantages include the possible differences in analyte concentrations 
between capillary and venous blood samples, which may lead to discrepancies in results. There is also a risk of 
contaminating the filter paper if the same person who administers the dosing also collects the sample 49.  
The effect of haematocrit on DBS assays, however, may be the greatest cause of variation in analysis results, 
since haematocrit has a significant effect on the viscosity of whole blood and is largely responsible for the extent 
to which sampled blood spreads on filter paper 55. Haematocrit is the volume percentage of RBCs in whole blood 
and can directly influence the accuracy of a DBS bioanalytical assay. The extent of the haematocrit effect on the 
assay depends on the analyte’s chemical and physical properties 56. A study conducted by Zheng et al.  analysed 
TFV and FTC in DBS and reported that samples with haematocrit values outside the range of 25–76%, did not 
meet the ±15% cut-off criteria required for accurate sample analysis, as set by the authors 47. The authors also 
observed increased mass spectrometer response, of both TFV and FTC, with increasing haematocrit 47. The 
analytes’ recovery is also affected by haematocrit and higher recovery is often observed at low haematocrit values, 
whereas lower recovery is often observed at high haematocrit values 57.  
The complications caused by varying haematocrit values can be avoided by analysing the DBS in its entirety, since 
this will eliminate any variation caused by non-homogenous spreading on the filter paper; however, using the 
whole DBS instead of punches will increase the importance of accurate volumetric application of blood to avoid 
variation, which makes sampling difficult for clinical sites 49. The effect of haematocrit can also be decreased by 
standardising the calibration standard’s haematocrit values closer to expected values; however, most DBS studies 
do not have any haematocrit information, making it impossible to compensate for varying haematocrit values 58. 
Recent studies describe a method that utilises potassium as a measure to elucidate haematocrit of DBS samples 
directly. Potassium is predominantly present intracellularly at concentrations 35 fold compared to those observed 
in the extracellular fluid, thus it is ideal for estimating haematocrit 58. However, this analytical approach is 
destructive to the sample and, therefore, is not ideal where sample volumes are limited. A non-destructive 
alternative has recently been developed and utilises noncontact diffuse reflectance spectroscopy to determine the 
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haematocrit of samples. The method has shown a significant correlation between the predicted haematocrit values 
and the true haematocrit values 59.  
2.3. Analyte Stability 
The correct storage and handling of clinical samples, standards, and quality controls (QCs) are essential for 
reproducibility of an assay. Stability should be calculated to determine adequate storage conditions and ensure 
reproducibility and reduce variation 46. Stability is analyte and matrix specific and, therefore, this needs to be 
considered for sampling, storage and transport of samples. 
A study done by Castillo-Mancilla et al. determined the stability of TFV-DP in DBS samples, by comparing samples 
stored at room temperature, 4⁰C and -20⁰C to samples stored at -80⁰C. Acceptable stability was defined as any 
value within 15% of the -80⁰C stored sample values 24. No change (-0.3%) was observed for samples stored at -
20⁰C, although this was not the case after seven months of storage. Samples stored at 4⁰C showed a % Difference 
of -6%; however, this was within the 15% acceptability range and was classified as stable. Samples stored at room 
temperature were not within the required 15% (-47%) and, thus, storage at this temperature does not allow 
acceptable sample stability 24. This significant deviation was apparent after one week of storage. TFV-DP stability 
can also be determined by monitoring TFV concentrations, since TFV concentrations significantly increased in 
samples stored at room temperature. This is due to the degradation of TFV-DP back to its parent compound 47. 
Thus, it is clear that TFV-DP DBS patient samples should be stored long term at -20⁰C or lower to maintain integrity 
of samples 47.   
2.4. Extraction 
As previously mentioned, LC-MS/MS has become the preferred bioanalytical technique; however, LC-MS/MS is 
plagued by limitations as a result of the complex nature of biological matrices 41,46,60. Biological samples contain 
background compounds, like salts, proteins, lipids, lipoproteins, and various other contaminants, which should be 
removed from samples prior to injection 60. The complexity of biological matrix constituents differs for each 
individual matrix, thus each matrix faces unique challenges requiring different approaches to be implemented 41. 
For example, plasma contains high concentrations of phospholipids, while whole blood needs to be lysed before 
analysis, and urine contains high levels of salts that need to be removed before injection into the mass 
spectrometer 61.  
Biological matrix effects can result in significant variation in LC-MS/MS analysis, due to ion suppression or 
enhancement, and the non-volatile nature of some matrix constituents 61. This occurs regardless of the use of 
electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI) 41,61. However, matrix effects can 
be reduced during the sample extraction process, when it succeeds in isolating and concentrating the analyte of 
interest, and also removes matrix components from the processed sample 41. Such extraction methods may 
require additional steps, depending on the selected biological matrix. Therefore, when selecting an extraction 
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approach, the chemical characteristics of the analytes of interest and the biological matrix must be taken into 
account 45. 
There are three core extraction approaches, namely protein precipitation (PP), liquid-liquid extraction (LLE), and 
solid phase extraction (SPE) 41. PP is the least laborious approach and has widely been used in bioanalytical 
methods 41. PP removes contaminants through the denaturation of proteins 41. This is often achieved by adding 
organic solvents to the biological matrix; however, it is not limited to this methodology and proteins can also be 
denatured by adding heat, strong acids or bases. The method of denaturation is selected based on the 
physiochemical properties of the analyte of interest 41. After denaturation, samples are centrifuged to draw 
denatured proteins to the bottom of the vial, leaving other components in the liquid layer 62. The supernatant is 
subsequently removed and used for quantitation 41. PP is widely considered as the least favourable extraction 
protocol for LC-MS/MS, since it only removes proteins and leaves various other matrix constituents in the 
processed sample 41. 
LLE is centred around affinity-based separation, where two immiscible solvents are added, allowing the analyte of 
interest to migrate to the solvent for which it has the most affinity 41,62. This is based on the hydrophobicity of the 
analyte of interest and solvents are strategically selected according to their immiscibility with the sample solution 
and compatibility with the analyte of interest 62. Even though it is a widely used technique, LLE has various 
limitations, including low or fluctuating recovery, it requires large sample volumes, and it may lead to poor 
selectivity and matrix effects when used in conjunction with mass spectrometry methods 41. Alternative extraction 
methods are required for polar analytes, due to the poor recovery of water-soluble polar analytes. This will lead to 
poor reproducibility and ultimately a less robust methodology 63. 
SPE was originally developed to substitute LLE; however, SPE is also centred around affinity based separation, 
although this approach chemically separates the various components of the sample by the use of solid particles 
64. These particles usually consist of chromatographic packing material and analytes are separated based on the 
analyte’s affinity for the stationary phase 41. SPE offers various advantages over other techniques, although it also 
has limitations, especially when working with hard to retain polar compounds. However, problems associated with 
LLE, namely incomplete phase separation, the use of expensive specialty glassware, and the use of large volumes 
of expensive organic solvents, can be circumvented with the use of SPE 64,65. SPE also does not require large 
sample volumes, making it ideal for DBS analysis. 
2.5. Mass Spectrometry 
Mass spectrometry (MS) is an analytical technique that isolates and detects species according to their mass-to-
charge (m/z) ratio. MS consists of three main components, namely an ionisation source, a mass analyser and a 
detector, and this is shown in Figure 2.1 66. The mass spectrometer converts the analyte of interest into gas phase 
ions, which is an essential step required for the detection of compounds 66. There are various MS sources that 
allow this reaction to take place, namely ESI, APCI, and atmospheric pressure photoionisation (APPI); however, 
only ESI will be discussed since it will be used in this study 66.  
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During ESI, ions are generated at atmospheric pressure by passing a solution of compounds through a small 
capillary that has a potential difference of more than 500 volts, relative to a counter electrode (Skimmer cone) 66. 
The precise voltage depends on the capillary diameter and the solvents used. An aerosol-like spray of charged 
droplets is created through a nebulisation process which is usually facilitated by an inert gas, like N2 67. Droplets 
will migrate from the capillary needle towards the skimmer cone as a result of the generated potential difference. 
As the droplets migrates, solvent evaporation occurs and the droplet diameter decreases as a result of the high 
temperature environment in the source 67. The decrease in droplet size leads to an increase in charge density, 
until it becomes unstable after reaching its Raygleigh limit, after which a cascade of Coulomb fissions occurs until 
gaseous ions are formed 67. 
 
 
Figure 2.1: Basic schematic of the three main components of a MS system 68. 
 
2.6. Liquid Chromatography   
Liquid chromatography is a separation technique in which a mobile phase is passed through an analytical column, 
packed with a stationary phase (i.e., the sorbent), resulting in separation of solutes in mobile phase. The latter 
being the consequence of differences in the physiochemical properties of the solutes 69. Each solute will have a 
certain affinity for the sorbent and during the transit time of solutes, they will interact with the sorbent to a varying 
extent based on the compounds affinity for each solute 69. Therefore, separation of compounds can be achieved. 
Conventional liquid chromatography is often used for preparative work and the purification and isolation of sample 
constituents. Recent advances in liquid chromatography utilizes small packing particles and high pressure for 
analytical separation of samples, referred to as high performance liquid chromatography (HPLC). The use of 
smaller particle sizes results in improved separation, resolution and column efficiency. This can be described by 
the Van Deemter equation, shown below: 
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𝐻 = 𝐴 + 𝐵 𝜇⁄ + 𝐶𝜇 
Where: 
H= Theoretical plate height 
A= Eddy (axial) diffusion 
B= Longitudinal diffusion 
C= Mass transfer 
µ=Linear velocity 
 
With the improvement in HPLC systems, lower linear velocities are attainable. This, accompanied with improved 
column chemistry, allows increased resolution and column efficiency 70.  
Reversed-phase high-performance liquid chromatography (RP-HPLC) separates molecules based on 
hydrophobicity. The separation is determined by the hydrophobic binding of the solutes dissolved in mobile phase 
to the immobilized hydrophobic ligands attached to the sorbent 69. Elution can proceed either by isocratic 
conditions, where the concentration of organic solvent is constant, or by gradient elution whereby the amount of 
organic solvent is increased over a period of time. The solutes are, therefore, eluted in order of increasing 
hydrophobicity 69. RP-HPLC has excellent resolution properties and can be maintained over a wide range of 
chromatographic conditions. RP-HPLC also provides experimental ease with which chromatographic selectivity 
can be manipulated through changes in the mobile phase 69.  
As a result of the highly polar nature of NRTIs and their phosphorylated metabolites, they are difficult to retain on 
conventional reversed-phase analytical columns. This encumbers the development of a multiplex method 
containing TFV and its metabolites. TFV has two pKa values at 3.8 and 6.7 and is highly hydrophilic (Log P= 
−1.6).71. TFV is very polar due to its phosphate group, making it difficult to retain on both reversed phase analytical 
columns and SPE cartridges 13. The quantification of NRTI, like TFV and TFV-DP, presents various obstacles that 
need to be overcome to achieve reliable results. Nucleotides are negatively charged at pH values above 2, making 
them even more polar, and thus further decreases their retention on traditional reverse phase columns 72,73. These 
negatively charged nucleotides can however, be separated with ionic interactions at the correct pH value 72. Anion 
exchange liquid chromatography separate negatively charged analytes through ionic interactions with a charged 
stationary phase, although this is often incompatible with ESI mass spectrometry, due to the non-volatile nature 
of some of the inorganic salts that are required to act as competing ions 72. These non-volatile inorganic salts often 
contaminate the ion-source and suppress ESI 72. Alternatively, formic acid can be added as a mobile phase 
modifier as this helps facilitate ionization in the ESI positive mode and retention on the analytical column 13. 
Improved retention is observed due to a decrease in the mobile phase pH, leading to NRTI reverting back to its 
unionised, and thus, less polar form.  
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All methods reviewed that allow the detection of TFV require an acidic solvent as a modifier. This facilitates 
ionisation when working in the positive mode of an ESI source and it also improves retention of TFV on a C18 
analytical column 13,74. LC-MS/MS-compatible acidic solvents that have been used to improve TFV retention and 
intensity, include formic acid, acetic acid, and trifluoroacetic acid, of which acetic acid has demonstrated the 
highest TFV sensitivity 13,74. When working with an ionisable compound like TFV, the pKa can be used as an 
indication of the level of ionization at a certain pH. Working with a mobile phase pH that is close to the pKa value 
will result in instability in retention times, ultimately leading to a less robust method. Alternative approaches will be 
discussed in section 2.8. and these include derivatisation reactions, ion-pairing, and ion-exchange 
chromatography. 
2.7. Existing Methods and Approaches for the Quantification of TFV and its 
Metabolites 
Various methods have been developed to measure nucleosides and their phosphate metabolites; these can be 
grouped into two distinct categories, namely direct and indirect approaches. Indirect approaches focus on the 
separation of analytes and their phosphate metabolites into separate fractions with the use of strong anion-
exchange SPE columns 13. The separated metabolite fractions are subsequently dephosphorylated to allow 
reverse phase analysis 13. The indirect approach is laborious, due to extensive sample pre-treatment, and often 
requires multiple analyses per sample. This leads to extra costs and is instrument-time demanding. The use of a 
direct approach can avoid these issues; however, greater chromatographic separation is required, due to the 
absence of the fractionation and subsequent dephosphorisation step in this method. The greater separation is 
especially necessary due to the possible degradation of analyte phosphate moieties in the ion-source 13. Direct 
methods often have to employ the use of ion-pairing reagents that increase the capacity factor of the analytes, 
leading to improved retention, resolution and baseline separation 75. A schematic depicting the two approaches 
can be seen in Figure 2.2. 
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Figure 2.2: A schematic representation of the direct and indirect approaches of analysing TFV and its metabolites. 
 
2.7.1. Indirect Approach 
To achieve reliable quantification, the indirect method requires the separation and subsequent dephosphorisation 
of nucleotide analogues and their metabolites 13. This is necessary due to the unstable nature of TFV-DP, TFV-
DP degrades to TFV in the ion-source, thus adequate baseline separation is required for a direct approach. The 
indirect method avoids this drawback through separation and subsequent dephosphorisation of the metabolites 
during SPE.  
A widely used method for the quantification of TFV and TFV-DP, was developed by Bushman et al. and includes 
the separation and quantification of mono-, di- and tri-phosphate metabolites of FTC, lamivudine and zidovudine.13. 
In the developed method, a lysed cellular matrix is run through Waters QMA SPE cartridges, followed by the elution 
and isolation of the nucleotide analogue phosphate fractions. Various solutions with differing potassium chloride 
concentrations are used to elute nucleoside analogues.13. The isolated nucleotide analogue fractions are 
subsequently dephosphorylated by adding acid phosphatase and incubating at 37⁰C for 60 mins. Phosphatase 
hydrolyses the phosphate of TFV-DP and reverts the metabolite back to TFV. The fractions are then sent through 
a Phenomenex Strata-X SPE cartridge, to desalt and concentrate the fractions.13. This method achieved 
measurable signals of reference standards at levels as low as 1 fmol/sample, which is equivalent to 0.30 fmol of 
TFV on an analytical column; however, similar levels were not measurable in extracted samples, due to the 
variable process efficiency. With the aim of increasing recovery, trifluoroacetic acid-containing SPE (Waters Oasis 
HLB cartridge) were tested. Even though the improved recovery was non-significant, trifluoroacetic acid is 
necessary for the retention of TFV on HLB cartridges. This may not be the case for other nucleotide analogues 
 27 
 
and the acetic conditions may even lead to instability. However, acetic conditions are required for TFV due to the 
difficulty encountered when attempting to retain TFV, which is mainly as a result of its polar nature and phosphate 
group 13,74,76. Considering that TFV-DP has added phosphate groups, more severe retention problems may be 
encountered when analysing this compound. 
One of the notable advantages of the indirect method is that it allows the quantitation of mono-, di-, and tri-
phosphates, without requiring the reference standards of the metabolites, which are often expensive. This is as a 
result of the dephosphorylation process reverting the metabolites back to the parent drug which is more stable, 
hence there are also less stability issues 13. 
 
2.7.2. Direct Approach 
The direct approach does not involve the separation and dephosphorisation of nucleotide metabolites, but rather 
the extraction and injection of the analytes in a single run. This minimises cost, labour and time; however, this 
approach requires adequate baseline separation, which may be problematic when working with polar molecules 
like TFV and TFV-DP.  
A TFV-DP direct method has been developed, although it was designed for PBMCs and not DBS 26. In the method, 
PBMC samples were processed by PP and analysed on a LC-MS/MS system. PBMC samples were centrifuged 
and a PP step (1:1 methanol: 1 mM ammonium phosphate solution) was subsequently performed on the samples. 
Followed by an evaporation step under an inert gas, after which the analytes were reconstituted with 1 mM 
ammonium phosphate and subsequently analysed on an AB Sciex API-5000 triple quadrupole mass 
spectrometer.26. The method had a dynamic range of 1–2500 ng/ml. The recoveries for TFV-DP in PBMC was 
approximately 100% using the methodology described in this study. This however, was not the case for the upper 
layer plasma cells studied, where the recovery of TFV-DP was a dismal 20% 26. 
Recently, a direct on-line LC-MS/MS method was developed that allows the quantitation of TFV, FTC and 3TC 
and their phosphate metabolites 73. The method uses an automated on-line weak anion exchange (WAX) SPE 
method, coupled with ion-pair chromatography to clean and separate the analytes of interest. The WAX column 
allows the concentration and separation of the analytes of interest 73. 1,5-dimethylhesylamine (1,5-DHMA) was 
used as an ion-pairing reagent to increase the retention time of polar analytes 73. However, this method was 
completed in macaque PBMCs and requires a dedicated mass spectrometer with 6 and 10 port column switching 
valves coupled to six single solvent line pump systems. The analytical method also had a total run time of 18 
mins.73. Taking into consideration instrument requirements and the lengthy run time, this method is not suitable 
for routine laboratory work.   
Stability is an issue when working with nucleotide analogue triphosphates, thus all extractions need to be carried 
out on ice to maintain analyte stability. This is especially applicable for the direct method, since metabolites are 
not dephosphorylated back to the more stable parent analyte. 
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The mobile phase pH values of previous developed methods for nucleoside triphosphates including TFV-DP and 
its parent drug TFV, ranging from 5–10.5, depending on the mobile phase modifiers, presence of an ion-pairing 
reagent, and the organic solvent used. When using an ion-pairing reagent, most studies used a gradient to elute 
the analytes 26,77. Both isocratic and gradient analytical runs have been reported for the analysis of TFV and TFV-
DP, although the direct method and methods that employ ion-pairing reagents use gradient elutions 26,77. 
2.8. Measurement of Nucleosides and Nucleotides 
Apart from retention issues, sensitivity and selectivity are also paramount in the detection of intracellular 
concentrations of nucleotide triphosphates, such as TFV-DP 38. The use of a chemical derivatisation reaction [i.e., 
using dansyl chloride (Dns-Cl)] will increase the hydrophobicity and chromatographic retention of analytes, on a 
traditional reverse phase column and will also increase the selectivity and sensitivity. As an alternative to Dns-Cl 
an ion-pairing reagent and ion-exchange chromatography will also be discussed. 
 
2.8.1. Dansyl Chloride Derivatisation 
Amine derivatisation reagents like Dns-Cl, fluorescamine, fluorenyl-methyl chloroformate, dabsyl chloride and a 
myriad of thiol containing o-phthalaldehydes (OPA) have extensively been used with the aim of improving 
selectivity and sensitivity of free amino acids assays and various other amine-containing analytes. Even though 
Dns-Cl and OPA are the most widely used amine derivatisation reagents, studies have shown that both Dns-Cl 
and OPA are suitable derivatisation reagents in the nano-mole concentration range; however, Dns-Cl is a superior 
derivatisation reagent in the pico-mole concentration range  38,78–81.  Dns-Cl derivatisation products are also more 
stable than those formed using OPA. This adds to its suitability as a derivatisation reagent; however, it does react 
with water, leading to the production of various hydrolysis products 78. Hydrolysis can be prevented by using 
minimum amounts of Dns-Cl or working at the optimal pH values 80.  
Dns-Cl reacts with primary aliphatic and aromatic amines (as seen in Figure 2.3) and should react with the amine 
groups on TVF and TVF-DP, leading to increased specificity and selectivity 38,76. This could allow the design of a 
direct multiplex method that could lead to a cost-effective and less laborious assay. 
Dns-Cl derivatisation yields are significantly influenced by pH, reaction time, reaction temperature, and Dns-Cl 
concentration 80. Derivatisation yields increase drastically with rising temperatures, as demonstrated in a study 
comparing the yield of reactions carried out at different incubation temperatures 80. A reaction temperature of 95⁰C, 
yielded up to 10 fold higher derivatised products when compared to solutions incubated at 40⁰C 80. However, the 
evaporation of the mobile phase at higher temperatures limit reaction temperature and most studies use 
temperatures ranging between 60–80⁰C 79–82. The optimal reaction time varied between most methods and 
appeared to be analyte and concentration specific, although most methods used an incubation period ranging 
between 30–60 mins 76,80,82. A pH of 9.5 is optimum for the derivatisation of unprotonated amine groups. When 
the reaction is carried out at pH values higher than 10.0, the reaction of primary amine groups with Dns-Cl is in 
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direct competition with the hydrolysis of Dns-Cl by hydroxyl groups or water 78. Adducts also form during the 
derivatisation reaction and should be minimised to achieve optimal sensitivity and selectivity. A study showed that 
Dns-Cl adduct yield decreases with increased Dns-Cl volumes 80. This was attributed to the decomposition of 
adducts, due to excess Dns-Cl 80. Most studies report using acetone to dissolve Dns-Cl, before addition to the 
biological samples 76,79,81. 
To ensure the reproducibility of the Dns-Cl derivatisation reaction, the reaction should be stopped after a 
designated reaction period. This is often accomplished by adding an acid to the reaction mixture after a specified 
incubation period 81,83. To decrease the interference of excess Dns-Cl in HPLC systems, alternatives like L-alanine 
can be added to stop the dansylation reaction, this works by reacting with excess Dns-Cl and stopping the 
formation of further derivatised products 78.  Glycine has also been used to react with excess Dns-Cl, after which 
the dansyl glycine was extracted with the use of C18 Sep-Pak cartridges 83. However, the addition of extra extraction 
steps should be avoided when working with small sample volumes or struggling with sensitivity.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
Special consideration should be given when adding a Dns-Cl derivatisation step to a method, since Dns-Cl is 
highly reactive and may react with internal standards (ISTD), especially if they contain an amine group. This is a 
problem when working with non-deuterated ISTD. When working with non-deuterated ISTD, the ISTD are chosen 
due to their ability to separate completely from analytes and an inertness to Dns-Cl 80.  However, when working 
with a deuterated ISTD the ISTD should be derivatised in order to compensate for reaction variability. Other 
reported complications include a decrease in analytical column life and most methods require a post run wash 
step, to remove impurities from the column. These wash steps consist of either MeOH or acetonitrile (ACN) 78,80. 
Incorporation of a reversed column flush before the injection of a new batch, has been shown to significantly 
prolong the life of an analytical column 78. Derivatised polyamines have also been reported to stick to polypropylene 
tubes, with larger polyamines binding more strongly to the tubes due to their higher charge 78. Recovery issues 
have been encountered when reconstituting derivatised polyamines, due to their solubility in certain organic 
solutions 78. 
A sensitive and selective LC-MS/MS method was developed for the simultaneous determination of gemcitabine 
(dFdC), an anti-cancer chemotherapy drug, and 2,2-difluoro-2-deoxyuridine (dFdU), its metabolite, using a Dns-
Cl derivatisation step 76. The derivatisation step was essential for retention and sensitivity of the compounds. The 
method used a pre-column derivatisation step that was performed in plasma without prior sample clean-up.  
Samples were subsequently extracted, using methyl tertiary-butyl ester (MTBE) 76. dFdC is similar to TFV in its 
chemical properties and mode of action. Much like TFV, dFdC is phosphorylated to its pharmacologically active 
metabolite intracellularly. The di- and tri-phosphorylated metabolites are responsible for the drug’s cytotoxic effect 
and dFdC and dFdU are very polar, like TFV, resulting in difficulty in attaining good resolution and retention on a 
reverse phase column 76. These issues were circumvented by adding a Dns-Cl derivatisation step. The 
derivatisation step was carried out by adding a 100 µl of 10 mg/ml Dns-Cl in acetone and 100 µl 100 mM sodium 
bicarbonate (pH 11) to plasma samples, followed by a vortex step and incubation at 60⁰C for 5 mins 76. The dansyl-
derivatives of dFdC and dFdU were then extracted using LLE by adding 1 ml of MTBE 76. Even though the method 
achieved its aim of determining dFdC and dFdU, no mention was made of determining the concentration of the 
phosphorylated metabolites of either dFdC or dFdU. The authors also do not mention whether these metabolites 
 30 
 
were degraded back to the parent drug during the Dns-Cl derivatisation reaction or whether the different fractions 
were used to determine the total dFdC and dFdU concentrations separately.  
The bulk of methods reported for the determination of amino acids contain an offline pre-column derivatisation 
step 80. SPE and LLE methods have been reported for the extraction of dansyl derivatives 80,83,84.  A study utilising 
off-line pre-column derivatisation added samples to 2 mol/l KHCO3-KOH with a pH of 9.8 and 20 mg/ml Dns-Cl. 
This was incubated at 80⁰C for 30 mins and the reaction was subsequently stopped by adding 20 µl of acetic 
acid.80.  
 
 
Figure 2.3: A depiction of the reaction of Dns-Cl with an amine group, leading to the formation of hydrochloric 
acid. Adapted from Hernández-Borges et al..85. 
 
2.8.2. Ion-Pairing Chromatography 
Ion-pair chromatography is a promising alternative to anion exchange chromatography, since it is compatible with 
mass spectrometers and leads to improved retention and chromatography 75. Using ion-pairing reagents as mobile 
phase additives allows the separation of ionic and highly hydrophilic substances on conventional reversed-phase 
analytical columns 75. Various ion-pairing reagents have previously been used in methods that quantify nucleotide 
analogues and were selected based on the physiochemical properties of analyte of interest 72,73. The addition of 
an ion-pairing reagent is necessary, since conventional reversed-phase separation is based on the hydrophobic 
interactions between the stationary phase and the analyte of interest. Hence, polar compounds, like TFV and its 
phosphorylated metabolites, will not interact with the hydrophilic stationary phase, leading to little to no retention 
and poor separation. The addition of an ion-pairing reagent leads to increased retention and separation of polar 
analytes 81,86,87. 
Ion-pairing reagents consist of an ionic end and a non-polar tail (hydrocarbon chain) 88. After addition to the mobile 
phase, the non-polar tail has strong interactions with the non-polar stationary phase. This leaves the ionic group 
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exposed and ionic species of the opposite charge will interact with the ion-pairing reagent, leading to significant 
increases in retention 88. This mechanism of action is shown in Figure 2.4.  
 
Figure 2.4: A visual representation of the mechanism of action of ion-pairing is shown: As can be seen a) is the 
bonded phase that is attached to b) the silica particles. The c) unattached ion-pairing reagent d) interacts with the 
stationary phase. The e) analyte of interest is injected into the mobile phase and f) interacts with the ionic group 
attached to the stationary phase 89. 
 
TFV and TFV-DP studies have reported the use of ion-pairing reagents and the most commonly used is 1,5-
DHMA. 73,77,90. However, its use may lead to a loss of sensitivity when compared to other more volatile ion-pairing 
reagents 72. The use of hexafluoroisopropanol and trimethylamine have been suggested as an alternative to 1,5-
DMHA. The combination of these ion-pair reagents have shown increases in selectivity and sensitivity compared 
to 1,5-DMHA 72. This is proposed to be a result of dynamic pH changes of the electrospray droplet that are caused 
by the selective evaporation and elimination of the more volatile HFIP anionic counter-ion. This approach has been 
used in a method designed to measure nucleotide triphosphates 72. In this method the mobile phase pH is 
approximately 8.3; but after evaporation of the electrospray droplets, the pH rises to 10 and, at this higher pH, the 
trimethylamine dissociates from the nucleotides and are released into the gas phase, resulting in increased 
ionisation; however, these ion-pairing reagents have not been used in combination with TFV or its metabolites 72.  
The mobile phase pH is of the utmost importance for ion paring reagents, since profoundly different elution 
characteristics have been reported due to pH changes. At higher pH values certain functional groups, like carboxyl 
groups, will ionise and lose affinity for the charged species of the ion-pairing reagent 88. 
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2.8.3. Ion-Exchange Chromatography 
Ion-exchange chromatography is a chromatographic technique that separates polar and ionic compounds based 
on ionic or electrostatic interactions 91. Ion-exchange analytical columns have charged ionic functional groups 
derivatised to the column’s stationary phase and can be subdivided into either cation-exchange or anion-exchange 
columns, depending on the charge of the attached functional groups 91. The type of ion-exchange column is 
selected based on the charge of the analyte of interest. Cation-exchange columns contain negatively charged 
functional groups and are used to separate cations; whereas, anion-exchange columns contain positively charged 
functional groups and are used to separate anions 91.  
The ionic strength of the mobile phase plays an essential role in the retention of compounds and elution is 
facilitated through the use of a mobile phase with a high ionic strength. Analyte elution can be achieved by either 
neutralisation of the analyte, neutralisation of surface functional groups, or the use of strong counter ions 91. This 
can be achieved using one of two approaches, namely a salt or pH gradient. 
When using a salt gradient, the ion of the analyte of interest must face competition from similarly charged counter 
ions present in the eluent. These ions will compete for the same oppositely charged ionic functional groups and 
will be displaced based on their charge density, thus, allowing separation of various analytes 91. However, this is 
often incompatible with ESI mass spectrometry, due to the non-volatile nature of some of the inorganic salts that 
act as counter ions, leading to ion suppression and the contamination of the ion-source 91. 
The pKa of the analyte of interest is essential when working with a pH gradient, since the pKa determines at which 
pH conditions a functional group will hold a charge. An acidic compound will be charged at two pH units above the 
pKa of the analyte, leading to the formation of an anion. The opposite is true when working with basic 
compounds.91. This is not only applicable for the analyte of interest, but also for the functional groups derivatised 
to the stationary phase. Thus, changing the pH of the mobile phase will lead to the formation of either a charged 
or neutral functional group, leading to the  retention or elution of the analyte of interest 91.  Various studies have 
reported the direct determination of TFV-DP using an anion exchange column with an ammonium acetate and pH 
gradient 26,92–94. Most studies used a pH of 6 for mobile phase A and a pH ranging between 9.5 and 10.5 for mobile 
phase B 26,92–94. The ammonium acetate concentrations varied significantly across the reviewed procedures; 
however, all the studies used a significantly lower ammonium acetate concentration in mobile phase A, ranging 
between 1–5 mM, and a high ammonium acetate concentration in mobile phase B, ranging between 10–750 
mM.26,92–94. This allowed the separation of TFV, TFV-MP and TFV-DP 92. 
 
2.9. Method Validation 
The validation of a bioanalytical method is a mandatory step that is required to demonstrate the suitability of an 
analytical method for its intended purpose, before the method may be implemented in routine application. 
Validation determines the reliability of the results obtained using the analytical method and is vital for 
pharmacokinetic, pharmacodynamic, bioequivalence, bioavailability, or toxicological studies 46. It is vital to 
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establish that the quantification of an analyte in a biological matrix is reproducible, reliable, and suitable for the 
application 95. General and specific standard operating procedures and good record keeping are key components 
to a successfully validated method. 
The method can undergo either a full, partial or cross-validation and the validation strategy is determined by the 
degree of method development. A full validation is required when a new drug or metabolite is added to the 
bioanalytical method or a newly developed method is implemented for the first time 46. According to EMA and FDA 
guidelines, a full validation must study all fundamental parameters including: selectivity, accuracy, precision, 
recovery, calibration curve, sensitivity, reproducibility, matrix effect, carry-over, and stability 46,95,96. In the present 
study a full validation of the newly developed method was conducted. The various validation parameter and special 
considerations are listed below: 
 
2.9.1. Internal Standards and Stock Solutions 
An ISTD is added to improve the precision of an assay and aids in the quantification of an analyte 44. The addition 
of an ISTD corrects for variability caused by dilutions, degradation, recovery, derivatization, evaporation, and 
various other instrumental parameters 44. The addition of an ISTD is essential when working with a multi-step 
sample preparation procedure 44. As has been mentioned before, LC-MS/MS is plagued by matrix effects and this 
is especially evident when working with an ESI source. When the matrix is introduced into the ion-source, the 
analyte of interest will compete for ionisation with various matrix constituents, leading to ion suppression 44. The 
degree of ion suppression varies between matrices and may vary between patient samples 44. Thus, this 
emphasises the need for an ISTD to correct for any variability in ionisation. However, the degree of ion suppression 
depends on the chemical structure of the analyte of interest; hence, an ISTD and the analyte of interest must have 
a sufficiently similar chemical structure to allow comparison. If the ISTD and the analyte of interest are not 
sufficiently similar, the degree of ion suppression may vary, leading to differences in the detector response and 
compromising the quantitation 44. Therefore, ISTD are usually either structural analogues or stable isotopically 
labelled analogues of the analyte of interest 44. Isotopically labelled analogues are preferred when used in 
combination with a mass spectrometer, since improved assay performance has been reported 44. Stable isotopes, 
such as deuterium 2H, 13C, 15N, and 17O, are usually substituted for atoms in isotopically labelled analogues. Three 
to eight atoms are usually substituted and the most commonly used isotopes are 2H and 13C 44. It is important that 
the stable isotopically labelled analogues contain three or more isotopes, since it should theoretically co-elute with 
the analyte of interest and a mass shift of three will allow the separation of the two compounds on the mass 
analyser. This should also help prevent cross-talk, which may impact the quantification of the analyte of interest. 
Cross-talk is due to the slow removal of ions from the collision cell and is often observed when analytes with the 
similar mass properties, structures, or monitored fragment ions are present 97. Deuterated ISTDs are often used 
since they are less costly and more abundant than 13C-, 15N-, and 17O-containing alternatives 44. 
Stock solutions must be made of certified analytical reference standards of a known purity. If the stock solution 
exists in a different state or buffer composition than the reference standards, stability must be determined 98. 
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Corrections must be made if the reference standard is not in the same chemical form as the analyte of interest 
(i.e. a free base or acid) and the solubility of the compound must be taken into account when choosing a 
reconstitution solution 98.  
 
2.9.2. Sensitivity 
Sensitivity refers to the minimum  concentration level at which a certain analytical method and instrument can 
deliver reliable quantitation results 96. At this concentration any sample analysed by the analytical method and 
instrument will deliver reliable results. This concentration is established as the LLOQ and any result below this 
concentration cannot be trusted and is labelled as below the limit of quantitation (BLOQ) 98.  
 
2.9.3. Selectivity and Specificity  
These two terms are often confused and according to the FDA and EMA, selectivity is defined as the ability to 
distinguish the analyte of interest and the ISTD from matrix components that may be present in the sample 46,95,96. 
However, EMA defines specificity as the ability to unequivocally measure the analyte of interest in the presence 
of exogenous or endogenous matrix constituents of the sample 46,95. These two terms are almost indistinguishable; 
however, specificity is absolute and selectivity is graded, thus a method is only considered to be specific when it 
is perfectly selective 46. The selectivity of an analyte is determined at the LLOQ by analysing six independent blank 
matrices as well as the analyte of interest spiked in matrix. The selectivity of the analytical method is assured when 
the response of interfering components is less than 20% of the analyte response at LLOQ 46. 
 
2.9.4. Accuracy and Precision 
Accuracy is described as the closeness of agreement of measured results to the true value of the analyte 46,95,96. 
Within-run accuracy and between-run accuracy should be evaluated, and this is expressed as Relative Error 
(%RE). Regulatory organisations recommend the use of a minimum of five replicates per concentration level, at a 
minimum of three concentrations levels 46,95,96. These three concentration levels consist of QCs and are made up 
of a low QC (which is within three times the LLOQ), a high QC (which is at least 75% of the upper calibration curve 
range) and a medium QC (which is between QC high and QC medium) 46,95. The deviation of the mean value 
should be within 15% of the true value, except at LLOQ, where a deviation of 20% is allowed 46,95,96. Thus, the 
deviation of the mean from the true value serves as the measure of accuracy. The formula for calculating accuracy 
is shown below: 
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% 𝑁𝑜𝑚𝑖𝑛𝑎𝑙 =
𝑀𝑒𝑎𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛
𝑁𝑜𝑚𝑖𝑛𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑡𝑟𝑎𝑡𝑖𝑜𝑛
 × 100 
 
The precision of an analytical method is defined as the closeness of multiple individual measures of a single 
homogeneous sample 46.  It can either be expressed as relative standard deviation or as the absolute coefficient 
of variation (%CV). The criteria are similar to that of accuracy, since the %CV should not exceed 15% for the QC 
samples and 20% for the LLOQ 46. The formula for the %CV is shown below: 
 
%𝐶𝑉 =
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑑𝑒𝑣𝑖𝑎𝑡𝑖𝑜𝑛
𝑀𝑒𝑎𝑛
× 100 
 
Precision can be evaluated with the same experiments used for the determination of accuracy. Within-run and 
between-run precision must also be determined. Within-run describes measurement of accuracy and precision by 
in a single run, while between-run describes the measurement of accuracy and precision from at least three runs 
analysed, on at least two different days 46. 
 
2.9.5. Recovery 
Recovery is defined as the ability of the method to extract the analyte of interest from a biological matrix 46,95,96. 
Recovery is determined by comparing the response of blank matrix spiked with a known concentration that has 
been extracted and one that hasn’t, thus representing 100% of the known concentration 46. There are no criteria 
for the recovery value; however, the recovery of an analyte and of the ISTD must be consistent, precise, and 
reproducible. Recovery experiments should be performed by comparing the analytical results for extracted 
samples at QC low, QC medium and QC high, with theoretical samples that represent 100% recovery. Recovery 
is calculated as: 
 
% 𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑀𝑒𝑎𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
× 100 
 
2.9.6. Matrix Effects 
The Matrix effect is specifically related to methods that use mass spectrometry and is defined as the effect of 
matrix constituents on the analysis of the analyte of interest. This may manifest as signal suppression or 
enhancement, impact on retention times, or elevated baseline signals 46. The presence of an internal standard 
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may minimise the effect of some matrix components. Matrix effects may be calculated using a minimum of six 
different blank sources of the appropriate biological matrix. Each individual biological matrix must be spiked at low, 
medium and high concentration levels and all matrix sources must be spiked with a single concentration of the 
ISTD. The %CV for the six different matrix sources should not exceed 5% 99. 
 
2.9.7. Carry-Over 
Carry-over is caused when a residual amount of analyte remains on the analytical system after an injection has 
been completed. Carry-over can be a serious obstacle for LC-MS/MS analysis, since it can affect the accuracy 
and precision of an assay 46. Carry-over has a greater effect on lower concentration samples and this is especially 
evident after the injection of a high concentration sample. Carry-over is assessed by including a blank sample after 
a high concentration sample or calibration standard at the upper limit of quantification (ULOQ) 46,95. The response 
of carry-over should not be greater than 20% of the LLOQ, and 5% for the ISTD 46. Carry-over is calculated as: 
 
%Carry − over =
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒𝑎 𝑜𝑓 𝑎 𝑏𝑙𝑎𝑛𝑘 𝑠𝑎𝑚𝑝𝑙𝑒, 𝑎𝑓𝑡𝑒𝑟 𝑖𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑈𝑃𝐿𝑂𝑄
𝑃𝑒𝑎𝑘 𝑎𝑟𝑒 𝑜𝑓 𝑎𝑛𝑎𝑙𝑦𝑡𝑒 𝑎𝑡 𝐿𝐿𝑂𝑄
× 100 
 
2.9.8. Stability 
To guarantee reliable and reproducible results, the stability of an analyte must be determined in stock solutions 
and in the relevant biological matrix 46. The conditions used in stability experiments should mimic conditions that 
may occur during sample handling and analysis 46. Stability samples should be compared to freshly made 
calibrators or QCs. At least three replicates at each of the low and high concentrations should be assessed. 
According to regulatory bodies, the deviation of calculated and nominal results should be within 15% for all stability 
analyses 46,95. Stability is calculated by the formula shown below: 
 
𝑆𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑀𝑒𝑎𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝑀𝑒𝑎𝑛 𝑟𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
× 100 
 
Regulatory bodies also require several other stability tests to ensure proper handling and storage. These tests 
include freeze/thaw stability, bench-top stability, long-term stability, stock solution stability, and auto-sampler 
stability 95. 
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2.10. Conclusion 
As has been discussed in detail, various alternative approaches are available for the quantification of TFV and 
TFV-DP in DBS. The current methodology entails the separation of the parent drug from the metabolite, followed 
by the back-conversion of all metabolites to the parent drug before analysing the samples on LC-MS/MS, which is 
a time-consuming process. The new method aims to reduce the time taken for each assay and the associated 
cost for the consumables, making the technology more accessible to local researchers with limited funding 
available. To do so, the various retention and sensitivity limitations associated with TFV and its metabolites will 
have to be addressed. The use of either a Dns-Cl derivatisation reaction, an ion-pairing reagent or anion-exchange 
chromatography should compensate for the associated limitations and allow for the development of a less 
laborious and cost-effective assay. 
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Chapter 3: Bioanalytical Method Development  
3.1. Introduction 
Prior to the implementation of a bioanalytical method, the method must be developed and subsequently validated, 
according to FDA and EMA guidelines 95,96. Possible approaches for the development of a direct LC-MS/MS 
method have been discussed in the previous chapter and this chapter will discuss the implementation of these 
approaches, with the aim of developing a direct LC-MS/MS analysis for TFV-DP. Three main approaches were 
investigated during the method development, namely derivatisation reactions, ion-pairing reagents and anion 
exchange chromatography.  
 
3.2. Experimental Development of Bioanalytical Method 
3.2.1. Analytes and Internal Standards 
TDF is an oral prodrug, which requires diester hydrolysis to form TFV, which is subsequently absorbed into the 
cell and becomes phosphorylated, leading to the formation of TFV-MP and, ultimately, TFV-DP 24. This study’s 
main analyte of interest is TFV-DP, since it can provide an indication of long-term adherence and is the 
pharmacologically active component. However, if the method also allows for the analysis of TFV it would be an 
added bonus, since TFV can be used as an indication of short-term adherence.  
For the development of the direct method TFV, TFV-MP and TFV-DP were monitored, to evaluate the 
chromatography of the analytes and allow the optimisation of baseline separation. Baseline separation is essential 
for the mitigation of cross-talk or back-conversion of the analytes in the ion-source.  
Stock solutions of TFV, TFV-MP and TFV-DP were prepared by weighing out the mass of the analyte into a 
container and dissolving the weighed-out mass in the appropriate volume of water to obtain the target 
concentration of 1000 μg/ml. All stock solutions were stored at approximately -80°C until required.  
An ISTD was added to the bioanalytical method to compensate for any variation, which may occur as a result of 
evaporation, derivatization, instrument parameters, degradation or recovery 44. The addition of an ISTD should 
also help mitigate the matrix effects, which affect the reproducibility and accuracy of the assay 44,100–102. As has 
been discussed in the previous chapter, matrix effects are caused by undetectable coeluting sample constituents 
that influence ion intensity by either causing ion suppression or enhancement. The degree of ion suppression or 
enhancement is also largely determined by the chemical structure of the analyte 44. Therefore, the choice of the 
ISTD is important, since it should mimic the analyte of interest as closely as possible 44. Structural analogues and 
stable isotopically labelled ISTDs are commonly used for this reason. In this study we selected stable isotopically 
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labelled ISTDs, since they will co-elute with the analytes of interest. Tenofovir diphosphate-13C5 (Adenine-13C5) 
and Tenofovir-D6 were selected as internal standards for TFV-DP and TFV, respectively. 
The following sections will discuss the development and implementation of the various assay approaches. The 
various limitations and restrictions encountered with each method will also be presented. 
 
3.3. Dansyl-Chloride Derivatisation Reaction 
As has been discussed in section 2.8.1., Dns-Cl is an amine reagent and reacts with the primary amine group on 
TFV and TFV-DP as shown in Figures 3.1 and 3.2, respectively. However, the rate and extent of this reaction is 
dependent on the reaction conditions and these must be optimised to achieve an optimal and reproducible yield. 
According to Kang et al. the following conditions impact yield, namely reaction temperature, Dns-Cl concentration 
and reaction time 80. The optimisation of these parameters will be discussed in section 3.1.1.-3.1.3. below. TFV-
DP was not used for the optimisation of the reaction parameters, due to stability concerns, thus all the reaction 
parameters were optimised using TFV. The reaction yield was monitored using an AB Sciex API 2000 Qtrap mass 
spectrometer at unit resolution in the multiple reaction monitoring (MRM) mode and Analyst® software version 
1.6.1. was used for all chromatographic data acquisition, peak integration and quantification. An ESI source was 
used for ion production and a Poroshell 120 (4.6 mm x 150 mm, 2.7 µm) analytical column was used to achieve 
chromatographic separation. 
Infusion solutions were prepared to identify the transitions of TFV and the TFV derivative. A solution of 500 ng/ml 
TFV in water was prepared for TFV, while the TFV derivative was investigated by preparing a solution containing 
1 µg/ml of TFV and of 1 µg/ml Dns-Cl in water. The solutions were infused into an AB Sciex Qtrap 2000 mass 
spectrometer using a Hamilton syringe set at a constant flow rate of 10 µl/min. 
The transitions of the protonated precursor ions that were monitored were m/z 288 to the product ion m/z 176 for 
TFV.    Stable Q1 precursor ions at m/z 521 were not observed for the dansyl derivative. The final Q1 scan of TFV 
is shown in Figures 3.3. The initial product ions for TFV is shown in Figures 3.4. 
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Figure 3.1: Depiction of Dns-Cl reaction with TFV with the empirical formula and molecular weight of the products 
and reagents. 
 
 
Figure 3.2: Depiction of Dns-Cl reaction with TFV with the empirical formula and molecular weight of the products 
and reagents. 
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Figure 3.3: Final Q1 scan of TFV, following an infusion of 500 ng/ml TFV in a mixture of water and methanol 
(50:50, v/v). 
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Figure 3.4: The initial product ions of TFV are presented. Exact molecular weight of TFV is 287.07 g/mol. 
 
The monitored dansyl derivative could not be seen in any of the chromatographic runs; however, a decrease in 
TFV intensity was observed with the addition of Dns-Cl. A representative chromatogram is shown in Figure 3.5 
comparing TFV before and after the addition of Dns-Cl. As can be seen in Figure 3.5, the TFV intensity decreased 
as Dns-Cl was added. In an attempt to improve the chance of observing a dansyl derivative, the reaction conditions 
were optimised. However, due to the inability to observe the dansyl derivative itself, the reaction yield had to be 
indirectly monitored. To do so the reaction yield was elucidated by monitoring the decrease in TFV in each sample. 
As the reaction took place, the initial TFV concentration would decrease and this decrease was used as an 
indication of reaction yield; a decrease in TFV taken to indicate an increase in reaction yield. However, to confirm 
that the decrease in concentration was not due to degradation, all the optimisation experiments contained a sample 
containing only TFV as a reference.  
There were also concerns that the decrease in TFV concentration was only due to a possible influence of Dns-Cl 
on the ion intensity and that the addition of Dns-Cl may lead to ion suppression. However, this was shown to not 
have a substantial effect, since the TFV signal did not significantly differ at room temperature with and without 
Dns-Cl (before any optimisation was completed) as can be seen in Figure 3.6. 
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Figure 3.5: A representative chromatogram of TFV A) before the addition of Dns-Cl and B) after the addition of 
Dns-Cl. The solutions used in chromatogram A and B were both incubated at 40 ⁰C for 10 mins. 
 
3.3.1. Reaction Temperature 
The reaction temperature plays an important role in yield; therefore, the optimisation of this parameter is essential  
80. Various incubation temperatures were tested to determine the optimal reaction temperature, and this was 
achieved by adding 1 µg/ml of TFV and 1 µg/ml Dns-Cl into a 1.5 ml Eppendorf and incubating the sample at the 
appropriate temperature for 10 mins. Samples were evaluated at 5 temperatures, namely room temperature, 40⁰C, 
60⁰C, 70⁰C and 100⁰C. Samples stored at room temperature were used as a reference and a second sample set 
containing 1 µg/ml TFV without Dns-Cl was placed at each temperature to monitor any temperature-related TFV 
degradation. Each reaction was repeated six times and the results of the quantification are shown in Figure 3.6. 
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Figure 3.6: Change in TFV concentrations due to the derivatisation of TFV and Dns-Cl at various incubation 
temperatures. Statistically significant yield changes are indicated with an asterisk (p ≤ 0.05).  
 
A statistically significant increase in the derivatisation reaction was observed with an increase in temperature 
above 60⁰C. This corresponds to observations made by Kang et al. 80. A two-sample t-test assuming unequal 
variance was used to determine statistical significance (P≤0.05). This was done by comparing the each of the 
temperatures to the room temperature sample, which served as the reference. Samples stored at 70⁰C and 100⁰C 
showed statistically significant (n=6, t=2.10, p=0.0017 and n=6, t=1.73, p=0.0039, respectively) reaction yield 
differences when compared to the room temperature reference. The highest reaction rate was seen at 100⁰C; 
however, TFV degradation was also observed at 100⁰C. The use of 100⁰C as an incubation temperature also 
posed practical problems, since the mobile phase evaporates at this temperature, leading to increased pressure. 
Therefore, 70⁰C was chosen as the ideal incubation temperature, and this temperature was used in all further 
optimisation experiments.  
 
3.3.2. Dns-Cl Concentration 
The ratio of the analyte to Dns-Cl also plays an essential role in the product yield. According to Kang et al., higher 
Dns-Cl ratios not only lead to a higher yield, but also reduce the amount of adducts formed 80. However, the Dns-
Cl concentration can only be increased to a certain level, due to possible loss of sensitivity attributed to ion 
suppression or contamination of the mass spectrometer. The optimal ratio of Dns-Cl to TFV was determined by 
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adding 0.1, 0.5, 1, 10 and 100 µg/ml Dns-Cl, respectively to 1 µg/ml TFV. This was subsequently incubated at 
70⁰C for 10 mins and injected onto the LC-MS/MS system.  
The 1 µg/ml Dns-Cl sample set was used as a reference and each concentration was compared to the reference 
separately. Statistical significance was determined by completing a two-sample t-test assuming unequal variance 
(P≤0.05). As can be seen in Figure 3.7, statistically significant differences) could only be observed when comparing 
the 0.1 µg/ml and 0.5 µg/ml sample set intensities to those of the reference (n=6, t=1.83, p=0.0021 and n=6, 
t=1.92, p=0.0024, respectively). Thus, increasing the concentration to a level higher than 1 µg/ml Dns-Cl would 
not lead to significant increases in yield. 
 
 
Figure 3.7: Changes in production yield as a result of varying Dns-Cl concentrations. 
 
3.3.3. Reaction Period 
According to Kang et al., the reaction period also has a significant effect on the reaction yield 80. To determine the 
optimal reaction period; 1 µg/ml Dns-Cl was added to 1 µg/ml TFV and subsequently incubated at 70⁰C for up to 
1 hour. The solutions were injected onto the LC-MS/MS system at time point zero (T0) and in 10-minute intervals 
thereafter. This was repeated in triplicate and the mean peak area values are shown in Figure 3.8. 
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Figure 3.8: The mean response of TFV samples incubated at 70⁰C were determined in 10-minute intervals and 
were repeated in triplicate. 
 
Figure 3.8 demonstrates that a decline in TFV is observed as reaction time increases and this reflects an increase 
in the reaction yield. However, only a marginal increase in reaction yield was observed after an incubation period 
of 10 mins. Therefore, extending the incubation period past a period of 10 minutes would not lead to a substantial 
increase in reaction yield. 
 
3.3.4. Dansyl Derivative Identification 
After the optimisation procedure, a mixture of 1 µg/ml Dns-Cl and 1 µg/ml TFV in water was reinfused after 
incubation at the optimised conditions. The solution was infused into an AB Sciex Qtrap 2000 mass spectrometer 
using a Hamilton syringe set at a constant flow rate of 10 µl/min. The expected transition of the dansyl derivative 
protonated precursor ion was not observed, as can be seen in the initial Q1 scan shown in Figure 3.9.  
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Figure 3.9: Initial Q1 scan of the expected protonated dansyl derivative precursor ion, which was generated by 
infusing a mixture of 1 µg/ml Dns-Cl and 1 µg/ml TFV in water after a 10-minute incubation step at 70⁰C. 
 
Protonated dansyl derivative precursor ions at m/z 521 were not observed with the optimised reaction and an 
incomplete reaction caused the decision to abandon this approach. 
 
3.4. Ion-Pairing Chromatography 
Ion-pairing chromatography was investigated as an alternative chromatography system for the direct determination 
of TFV-DP. This approach has been used in various studies to quantify NRTIs 36,77,103–111. Ion-pairing reagents can 
be utilized to increase the retention of polar compounds, which are difficult to retain on traditional reverse phase 
analytical columns. TFV-DP and TFV-MP may revert to their parent compound once inside the heated mass 
spectrometer ion source. Therefore, it is essential to obtain baseline separation between TFV, TFV-MP and TFV-
DP. To normalise and simplify the data and allow a comparison between various solvents, pH values, ion-pair 
reagent concentration and various analytical columns, capacity factors of each analyte were calculated. The 
formula used to calculate capacity factors is shown below: 
𝐾′ =
(𝑇𝑅 − 𝑇0)
𝑇0
 
Where: 
• TR  is the retention time of the analyte 
• T0  is the dead volume. 
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3.4.1. Determining the Optimal Ion-Pairing Reagent 
The correct pH of a solution is essential when working with ion-pairing reagents and dictates whether a paired ion 
will form or not 112. The correct pH is dependent on the pKa of either the analyte or ion-pairing reagent, since both 
the analyte and ion-pairing reagent must be charged to interact 112. Therefore, to identify the optimal ion-pairing 
reagent the capacity factors must be determined for each analyte over a broad pH range. 
The capacity factor of each analyte was determined using a 1 µg/ml working solution prepared in water. These 
solutions were injected onto a Kinetex EVO C18 (50 mm x 2.1 mm, 1.7 µm) column coupled to a HPLC-UV 
spectrometer. A UV detector was used for method development, due to possible source contamination that may 
occur due to the ion-pairing reagents and the column was selected due to its high pH range that could withstand 
the unadjusted pH of the solvents.  All capacity factors were determined with isocratic methods. Each analyte was 
injected individually to determine its retention time and capacity factor over a pH range of 6–10, and an unadjusted 
mobile phase of pH 10.6. Two ion-paring reagents were investigated over the pH range, namely 1,5-DMHA and 
N,N-DMHA. The structure of the two ion-pairing reagents are shown in Figure 3.10. A concentration of 10 mM of 
either 1,5-DMHA or N,N-DMHA was added to a mixture of 5 mM ammonium acetate in water and methanol (70:30, 
v/v). The solutions were adjusted to the desired pH using acetic acid.  
 
 
 
 
1,5-Dimethylhexylamine N,N-Dimethylhexylamine 
Figure 3.10: The structures of 1,5-DMHA and N,N-DMHA. 
 
Most studies use 1,5-DMHA to retain TFV; however, N,N-DMHA is less expensive and more readily available and 
therefore it was also investigated as a prospective affordable alternative 106,108.  
Representative chromatograms of each ion-pairing reagent are shown in Figure 3.11. The chromatograms were 
observed by adding 10 mM of the respective ion-pairing reagent to a mixture of 5 mM of ammonium acetate in 
water and methanol (70:30, v/v) with an unadjusted pH. A 10 µg/ml of each analyte was injected into the HPLC 
system. Figures 3.12 and 3.13 depict separate injection of each of these analytes along with a blank sample. 
Figure 3.12 and Figure 3.13 presents the chromatograms for 1,5-DMHA and N,N-DMHA, respectively.  
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Figure 3.11: The chromatograms above show TFV, TFV-MP and TFV-DP separated with an isocratic run using 
10 mM of A) 1,5-DMHA and B) N,N-DMHA as ion-pairing reagents.  
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Figure 3.12: The representative chromatograms above were generated using an isocratic run with a mobile phase 
consisting of a mixture of 10 mM 1,5-DMHA and 5 mM of ammonium acetate in water and methanol (70:30, v/v) 
with an unadjusted pH. The following solutions were injected A) Blank, B) 10 µg/ml TFV, C) 10 µg/ml TFV-MP and 
D) 10 µg/ml TFV-DP. 
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Figure 3.13: The representative chromatograms above were generated using an isocratic run with a mobile phase 
consisting of a mixture of 10 mM N,N-DMHA and 5 mM of ammonium acetate in water and methanol (70:30, v/v) 
with an unadjusted pH. The following solutions were injected A) Blank, B) 10 µg/ml TFV, C) 10 µg/ml TFV-MP and 
D) 10 µg/ml TFV-DP. 
 
From the representative chromatograms it is clear that the 1,5-DMHA (Figure 3.13A) has a far superior separation 
capacity. Adequate baseline separation was observed in N,N-DMHA chromatograms; however, the resolution was 
poor and thus further optimisation was required. With the addition of TFV-DP an additional peak was also observed 
with a retention time of 32 minutes. 
There are various reports of decreased signal intensities associated with the use of ion-pairing reagents on ESI 
mass spectrometers 102,113,114. Therefore, the difference in signal suppression between 1,5-DMHA and N,N-DMHA 
was investigated. A marked decrease in signal intensity was observed when using N,N-DMHA as mobile phase 
additive. A 30% decrease in TFV-DP signal intensity was observed when comparing TFV-DP infused with N,N-
DMHA to TFV-DP infused with 1,5-DMHA, as seen in Table 3.2. Therefore, N,N-DMHA was not used for further 
experiments.  
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Table 3.1: Summary of infusion results of TFV-DP with either 1,5-DMHA or N,N-DMHA 
 
500 ng/ml TFV-DP 
1,5-DMHA N,N-DMHA 
TFV-DP signal intensity TFV-DP signal intensity 
Sample 1 380000 250000 
Sample 2 390000 270000 
Sample 3 380000 280000 
Average 383333.33 266666.67 
STDEV 5773.5027 15275.2523 
%CV 1.5 5.7 
%Difference   -30.4 
 
 
3.4.2. Determining the Optimal pH for 1,5-DMHA 
Capacity factors of each analyte at different pH values were determined using 1,5-DMHA as the ion-pairing reagent 
and a Kinetex EVO C18 (50 mm x 2.1 mm, 1.7 µm) analytical column. Clear baseline separation of the three 
analytes were observed at mobile phase pH values higher than 9 (a representative chromatogram is shown in 
Figure 3.11 A). 
The front of the Kinetex C18 EVO column was determined to be ~1.570 min and retention time and capacity factors 
for TFV, TFV-MP and TFV-DP are shown in the Table 3.3. From the results it is evident that the retention time for 
TFV-DP is the greatest at the unadjusted pH and that the opposite is true for both TFV and TFV-MP. Therefore, 
the greatest baseline separation for TFV-DP would be achieved with a mobile phase with an unadjusted pH. 
 
Table 3.2: Capacity factors of TFV and its metabolites at various mobile phase pH values. 
Mobile Phase conditions TVF TFV-MP TFV-DP 
TR K’ TR K’ TR K’ 
10 mM 1,5-DMHA Unadjusted pH, 30% MeOH 4.76 2.04 7.75 3.94 16.02 9.21 
10 mM 1,5-DMHA pH 10, 30% MeOH 4.93 2.14 8.15 4.19 13.81 7.80 
10 mM 1,5-DMHA pH 9, 30% MeOH 4.94 2.14 8.15 4.19 13.64 7.69 
10 mM 1,5-DMHA pH 8, 30% MeOH 5.11 2.26 8.44 4.37 13.84 7.82 
10 mM 1,5-DMHA pH 7, 30% MeOH 5.07 2.23 8.39 4.35 13.62 7.67 
10 mM 1,5-DMHA pH 6, 30% MeOH 4.90 2.12 8.23 4.24 13.52 7.61 
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3.4.3. Determining the Optimal Concentration of 1,5-DMHA 
The concentration of 1,5-DMHA was increased to observe the effect on the retention time of the analytes. A higher 
concentration of 20 mM was tested and a significant increase in retention time was observed accompanied by an 
increase in the baseline separation between TFV and TFV-MP. This can be seen in the representative 
chromatograms in Figure 3.14. 
 
Figure 3.14: The chromatograms above shows TFV, TFV-MP and TFV-DP separated in an isocratic run with A) 
10 mM of 1,5-DMHA and B) 20 mM Ammonium Acetate in 30:70 MeOH/H2O (v/v).  
 
3.4.4. Determining the Optimal Mobile Phase  
In order to develop a gradient method, which would reduce runtime and improve peak shape, the effect of the ratio 
of the organic to the aqueous phase was investigated. The capacity factors for each analyte was determined over 
an organic mobile phase range of 20% to 80% (MeOH/H2O, v/v). The results of this experiment are shown in 
Figure 3.15. All the mobile phases consisted of a mixture of 10 mM 1,5-DMHA with 5 mM ammonium acetate and 
an unadjusted pH at the respective organic/aqueous ratios. 
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Figure 3.15: The figure shows the capacity factors of TFV, TFV-MP and TFV-DP in a mobile phase consisting of 
a mixture of 10 mM 1,5-DMHA and 5 mM ammonium acetate in water and methanol with an unadjusted pH. 
 
Figure 3.15 illustrates the relationship between the percentage of organic solvent (v/v) and capacity factors of TFV, 
TFV-MP and TFV-DP. An increase in the percentage of organic solvent (methanol) resulted in a decrease in the 
capacity factors of all three analytes. There is a marked decrease in the capacity factor of TFV-DP when the 
percentage of organic exceeds 30% (v/v). 
All previous experiments were carried out using isocratic runs; however, a gradient method was developed to 
improve resolution and decrease the runtime. Initially the mobile phases would have consisted of a mixture of 10 
mM 1,5-DMHA and 5 mM ammonium acetate in 100% (v/v) water for mobile phase A and 100% (v/v) methanol 
for mobile phase B. However, 1,5-DMHA was not soluble in 100% water and thus required a portion of methanol. 
The 1,5-DMHA ion-pairing reagent was only soluble in mobile phases consisting of 30% MeOH (v/v) and higher. 
Therefore, the following two mobile phases were selected: 
A: A mixture of 10 mM 1,5-DMHA with 5 mM ammonium acetate in water and methanol (70:30, v/v) with an 
unadjusted pH. 
B: A mixture of 10 mM 1,5-DMHA with 5 mM ammonium acetate in water and methanol (10:90, v/v) with an 
unadjusted pH. 
The gradient method used can be seen in Table 3.4 and a representative chromatogram achieved using this 
method is shown in Figure 3.16. Baseline separation was achieved between TFV and its two metabolites. 
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Table 3.3: The gradient flow schedule of ion-pairing method. 
Time (min) Flow rate (µl/min) 
Mobile phase 
A (%) B (%) 
0.0 100 90 10 
2.0 100 90 10 
8.0 100 10 90 
9.0 100 10 90 
9.3 100 90 10 
12.0 100 90 10 
 
 
Figure 3.16: A representative chromatogram achieved using a gradient method, showing TFV-DP (Red), TFV-MP 
(Green) and TFV (Blue). 
 
The method was subsequently transferred from an AB Sciex 2000 QTRAP to an AB Sciex 5500 with the aim of 
improving sensitivity. After optimisation, a calibration curve consisting of eight TFV-DP working solutions ranging 
from 40 ng/ml to 4800 ng/ml was designed to assess the linearity of the method over the calibration range. 
Representative chromatograms that formed part of the curve are shown in Figure 3.17. The curve was calculated 
with a quadratic regression using a weighting of 1/x. The calibration curve is shown in Figure 3.18 and had a r-
value of 0.9945.  
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Figure 3.17: The representative chromatograms of TFV-DP working solutions with concentrations of A) 2400 
ng/ml and B) the LLOQ at 40 ng/ml. 
 
 
Figure 3.18: A TFV-DP working solutions ranging from 40 ng/ml to 4800 ng/ml (r-value of 0.9945).  
 
It is important to note that the current indirect DBS method has been validated over a range of 139–5546 
fmol/punch (2–124 ng/ml) and, therefore, the developed method would require a similar or lower LLOQ, otherwise 
it could not be used to replace the current indirect method since a similar level of sensitivity is required. The LLOQ 
reached using this ion-pairing method was 40 ng/ml, which is equivalent to 2785 fmol/punch. Therefore, this 
method was clearly not sensitive enough to be used as an alternative to the current indirect method. 
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3.5. Anion Exchange Chromatography   
The polar nature of nucleotides makes it difficult to retain these analytes using traditional reverse phase 
chromatography. Nucleotides are negatively charged at pH values above 2, making them even more polar 72,73. 
These negatively charged nucleotides can, however, be separated with ionic interactions at the correct pH value.  
The retention and separation of nucleotides can thus be achieved using anion exchange liquid chromatography, 
which separates negatively charged analytes through ionic interactions with a charged stationary phase. This is 
especially useful because of the formation of ion pairs between the negatively charged nucleotide phosphate 
groups and the stationary phase 72.  
Therefore, anion exchange chromatography was investigated as an alternative to ion-pairing chromatography. A 
Thermo BioBasic AX, (50 mm × 2.1 mm, 5 µm) column was selected as the anion exchange column of choice. 
The chromatography was developed using an AB Sciex QTRAP 5500 mass spectrometer coupled to an Agilent 
1260 HPLC system. This system was selected due to its higher sensitivity, which would allow the detection of 
lower analyte concentrations. 
   
3.5.1. Mass Spectrometry  
For MS analysis infusion solutions of TFV-DP, TFV-MP, TFV, and the TFV-DP deuterated internal standard were 
made from the previously prepared stock solutions. The stock solutions were used to prepare working solutions 
with a concentration of 0.1 µg/ml in a mixture of water and acetonitrile. The solutions were infused into an AB 
Sciex Qtrap 5500 mass spectrometer using a Hamilton syringe and set at a constant flow rate of 10 µl/min. This 
was done to obtain the mass spectra of the protonated molecular ions and their fragments. The quantitation 
method was set at unit resolution and was in the MRM mode. The transitions of the protonated precursor ions 
monitored were m/z 448.0 and 452.9 to the product ion m/z 350.0 and 354.9 for TFV-DP and the TFV-DP 
deuterated internal standard, respectively (Figure 3.19 and Figure 3.20). TFV-MP and TFV transitions were also 
added to the quantitation method to observe the retention times of these moieties during the chromatography 
development and to ensure adequate baseline separation of these compounds. The transitions of the protonated 
precursor ions monitored for TFV and TFV-MP were m/z 288.0 and 368.0 to the product ion m/z 176.0 and 269.9, 
respectively (Figure 3.21 and Figure 3.22). A DELL® Windows® XP computer was used as interface for the LC-
MS/MS system and Analyst® software version 1.6.2. was used for all chromatographic data acquisition, peak 
integration and quantification.  
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Figure 3.19: Initial product ion mass spectrum of TFV-DP. The molecular weight of TFV-DP is 447.17 g/mol and 
therefore the expected protonated precursor ion is observed at m/z 448. 
 
 
Figure 3.20: Initial product ion mass spectrum of the deuterated internal standard of TFV-DP. The molecular 
weight of the deuterated internal standard is 452 g/mol and therefore the expected protonated precursor ion is 
observed at m/z 453. 
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Figure 3.21: Initial product ion mass spectrum of TFV. The molecular weight of TFV is 287.21 g/mol and therefore 
the expected protonated precursor ion is observed at m/z 288.  
 
 
Figure 3.22: Initial product ion mass spectrum of TFV-MP. The molecular weight of TFV-MP is 367.19 g/mol and 
therefore the expected protonated precursor ion is observed at m/z 368. 
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3.5.2. Detection 
Mass spectrometer parameters are presented in Table 3.5 to 3.7. 
 
Table 3.4: Scan Description 
Scan Type: MRM 
Polarity: Positive 
Pause Time (ms) 5 
 
Table 3.5: Source settings  
Split 1:5 
CUR (curtain gas)  50 
IS (Ion-spray voltage) (V) 4500 
TEM (source temperature) (˚C) 500 
GS1 (Nebuliser gas)  40 
GS2 (Turbo gas)  70 
CAD (Collision gas)  2 
CEM (Channel electron multipliers) (eV) 2700 
 
Table 3.6: Tandem mass spectrometer settings 
 TFV-DP 
TFV-DP 
ISTD 
TFV TFV-MP 
Dwell time (msec) 150 150 150 150 
Entrance potential (V) 10 10 10 10 
Delustering potential (V) 136 151 121 111 
Collision energy (eV) 23 23 33 27 
Collision cell exit potential (V) 28 26 14 22 
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3.5.3. Chromatography 
A Thermo BioBasic AX (50 mm × 2.1 mm, 5 µm) column was selected as the analytical column of choice. One of 
the main aims during chromatography development was to separate TFV and TFV-MP from TFV-DP (analyte of 
interest) on the analytical column. The reason for the concern relates to possible cross-talk, thermal back-
conversion in the ion source, and ion enhancement or suppression that may be caused by TFV and TFV-MP 
during TFV-DP quantification. Various organic solvents, mobile phase pH’s and additives were investigated with 
the aim of obtaining optimal chromatography, adequate retention, and baseline separation between TFV-DP and 
its precursors analytes. The organic solvents evaluated consisted of either methanol and water or acetonitrile and 
water, with different solvent strengths ranging from 10–50% organic (v/v). The analytes were eluted using a pH 
gradient. A solvent with a low pH was used at the start of the run, allowing analyte retention. The gradient was 
switched over time to a high pH to allow the elution of the analytes. The two mobile phases that yielded the optimal 
chromatography and baseline separation are shown below: 
Mobile phase A: A mixture of 10 mM ammonium acetate in water and acetonitrile (70:30, v/v), adjusted to pH 6 
with acetic acid. 
Mobile phase B: A mixture of 2 mM ammonium acetate in water and acetonitrile (70:30, v/v), adjusted to pH 10 
with ammonium hydroxide. 
A gradient elution method was designed using the mobile phases shown above and the gradient flow schedule is 
shown in Table 3.8. The gradient method was designed to limit the amount of time in which mobile phase B (pH 
10) was pumped at a maximum percentage of the flow. This was done to increase the longevity of the analytical 
column, since the mobile phase pH is on the upper limit of the analytical column’s pH range. The flow rate was 
initially set at 400 µl/min; however, the effect of increased flow rate on the column pressure and chromatography 
was investigated in increments of 50 µl/min. The peak shape and separation of the analytes improved with an 
increase in flow rate; however, this could only be increased to 700 µl/min due to pressure concerns. 
Table 3.7: Gradient flow schedule 
Total Time (min) Flow Rate (µl/min) Line A (%) Line B (%) 
0.0 700 100 0 
0.4 700 50 50 
1.1 700 50 50 
1.2 700 5 95 
2.4 700 5 95 
2.6 700 100 0 
3.5 700 100 0 
 62 
 
 
Representative chromatograms demonstrating the separation achieved with the developed gradient method are 
shown in Figure 3.23. It is important to note that TFV-DP is the analyte of interest. Therefore, chromatography 
was only optimised for TFV-DP, which is shown in the top panel (A). Chromatography of the other two analytes, 
namely TFV and TFV-MP, was not optimised as the only aim was to separate the analytes from TFV-DP. 
 
 
Figure 3.23: Representative chromatographs of A) TFV-DP (Top panel) B) TFV-MP and C) TFV.  
 
Various needle wash solutions were investigated for their ability to reduce HPLC-injection carry-over. These 
solutions consisted of several organic solvents, including methanol, acetonitrile and isopropanol. The solutions 
were investigated with different solvent strengths ranging from 10–60% organic (v/v). The pH of the needle wash 
solution was also adjusted with pH’s ranging between 5–10.5. The needle wash solution that resulted in the least 
amount of carry-over consisted of a mixture of 5 mM ammonium acetate in water and acetonitrile (90:10, v/v), 
adjusted to pH 9 with ammonium hydroxide. The percentage carry-over was calculated by injecting a TFV-DP neat 
solution equivalent to a concentration of 6400 fmol/punch and subsequently injecting a blank sample, consisting 
of water (reconstitution solution). The peaks in the blank sample were then quantified and compared. A decrease 
in carry-over was observed in all needle wash solutions; however, carry-over was still present. We hypothesised 
that this may have been due to some analyte being retained on the injector switching valve and therefore a custom 
injection program was created to decrease any residual analyte that may have remained on the autosampler 
switching valve. This custom injection program is presented in Table 3.9, which also depicts the autosampler 
settings. The use of the custom injection program led to a 10% decrease in the peak area of the peak seen in the 
blank. However, carry-over was still observed.  
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Table 3.8: Autosampler settings 
Pump type Agilent 1260 Binary Pump 
Flow Rate 0.700 ml/min 
Autosampler Type Agilent 1260 High Performance Autosampler 
Sample arrangement  96-well plate 
Injection volume 20 μl 
Autosampler 
Temperature 
8°C 
Custom injection 
program 
1. DRAW def. amount from sample, def. speed, def. offset 
2. WASH NEEDLE with default wash parameters 
3. INJECT 
4. REMOTE start pulse, duration 60*12.5 msec 
5. WAIT 3.3 min  
6. VALVE bypass 
7. WAIT 0.50 min  
8. VALVE mainpass 
9. VALVE bypass 
10. VALVE mainpass 
11. REMOTE start pulse duration 120*12.5 msec 
 
In an attempt to mitigate any possible carry-over, stainless-steel tubing was exchanged for peek tubing and two 
wash injection steps were added to rinse both the column and the tubing. The two wash steps both consisted of 
gradient methods and these are depicted in Tables 3.10 and 3.11. The aim of the two wash steps were to remove 
the residual analyte from the HPLC system. The wash step injection solution consisted of a mixture of 2 mM 
ammonium acetate in water and acetonitrile (70:30, v/v), adjusted to pH 10 with ammonium hydroxide. No carry-
over was observed after the addition of the two wash steps. As can be seen in Figure 3.24. 
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Table 3.9: The gradient method of wash step 1. 
Total Time 
(min) 
Flow Rate 
 (µl/min) 
Line A 
 (%) 
Line B 
(%) 
0.00 700 5 95 
1.00 700 5 95 
1.10 700 100 0 
 
Table 3.10: The gradient method of wash step 2. 
Total Time  
(min) 
Flow Rate  
(µl/min) 
Line A  
(%) 
Line B  
(%) 
0.00 700 5 95 
0.50 700 5 95 
0.65 700 100 0 
3.50 700 100 0 
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Figure 3.24: Representative chromatograms are shown illustrating the carry-over after adding the wash steps. 
The following injections were made: A) Blank; B) 6400 fmol/punch neat solution; and C) Blank. 
 
3.5.4. Extraction Method  
Sample processing and extraction are essential for the removal of endogenous matrix components that may hinder 
or interfere with the analysis of the analyte of interest 101. There are three main approaches to sample extraction, 
namely, PP, LLE, and SPE 41.  The use of an ion-pairing solid phase extraction (IP-SPE) was initially investigated 
to allow for the optimal removal of sample constituents. IP-SPE follows the same steps and procedure required 
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for traditional SPE; however, it utilises ion-pairing reagents to increase the retention of the analyte of interest on 
the extraction cartridge 106. This is especially useful when working with highly polar compounds, like TFV-DP. 
During traditional SPE, a solution is added to the SPE cartridge prior to the biological sample to equilibrate the 
cartridge. In IP-SPE an ion-pairing reagent is added to the solutions used for the equilibration, loading and wash 
steps to help retain the analyte of interest 106. 1,5-DMHA was selected as the ion-pairing reagent and the 
equilibration solution consisted of a mixture of 10 mM 1,5-DMHA and 5 mM ammonium acetate in water and 
methanol (80:20, v/v) with an unadjusted pH. One millilitre of the equilibration solution was added to the cartridge, 
which would prepare the cartridge for sample loading. The lysate of the biological sample was subsequently added 
to the cartridge in the loading step. This was followed by a wash step, which consisted of the addition of one 
millilitre of a mixture of 10 mM 1,5-DMHA with 5 mM ammonium acetate in water and methanol (70:30, v/v) with 
an unadjusted pH. In the final step, namely the elution step, one millilitre of a mixture of 5 mM ammonium acetate 
in water and methanol (10:90, v/v) with an unadjusted pH was added to the cartridge to elute the analyte of interest. 
The elution solution was subsequently dried down and reconstituted with 150 µl of water and injected onto the LC-
MS/MS system. However, the recovery of this extraction method was only 40%. Various studies have shown that 
the use of an ion pairing reagent may lead to signal suppression and decreased sensitivity 102,114. Thus, the low 
recovery accompanied with concerns of possible exogenous ion suppression due to residual 1,5-DMHA in the 
elution solution, led to the dismissal of this approach. 
A simpler extraction approach was followed. PP with phospholipids removed using Phree columns was 
investigated.  
The sample extraction procedure started with the removal of the DBS sample from storage, which were 
subsequently left on the bench at room temperature for 20 minutes. After the 20 minutes three 3 mm DBS aliquots 
were punhed from the respective DBS cards and placed into a 1.5 ml Eppendorf tube.  
The TFV-DP internal standard was added to the lysate solution, which consisted of a mixture of water and 
methanol (30:70, v/v). The internal standard concentration in the lysate was prepared to a concentration equivalent 
to 200 fmol/punch. Each Eppendorf tube received 0.5 ml of the lysate solution; however, when the STDs and QCs 
were prepared, 60 µl of each STDs and QC level were added to their respective tubes. To compensate for the 
addition of the 60 µl in the STDs and QCs, 60 µl of water was added to the Eppendorf tubes of the blank and 
unknown samples. The tubes were subsequently sonicated for approximately 10 minutes at room temperature.  
A 1 ml Phree phospholipid removal SPE cartridge was used to help reduce the exogenous matrix effect. SPE was 
performed using a Speedisk® 48 SPE positive pressure system. The cartridges were conditioned with 1 ml 
methanol, before samples were added. After the sonication step 500 µl of the lysate was removed from the 
Eppendorf tube and placed into the conditioned 1 ml Phree phospholipid removal cartridge. The analytes were 
subsequently eluted into disposable borosilicate glass tubes. The glass tubes were placed in a heating block 
(Stuart® block heater, 40°C) and evaporated to complete dryness under a gentle stream of nitrogen for 
approximately 30 minutes. The extract was reconstituted in 150 µl of water and subsequently vortexed for 30 
seconds, before being transferred to a 96-well plate. 
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The newly developed direct LC/MS/MS assay covered a range of 50 to 6400 fmol/punch as presented in Figure 
3.25. 
 
 
 
Figure 3.25: Calibration curve of standards that range from 50 to 6400 fmol/punch (r=0.9985). 
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Chapter 4: Final Method 
 
Due to the sensitivity issues and the highly polar nature of TFV-DP, various approaches were investigated in an 
attempt to develop a more cost effective and less laborious direct method. The investigation of the various 
approaches were discussed in Chapter 3; however, this chapter will summarise the final bioanalytical method 
procedure, which ultimately underwent the validation procedure.  
4.1. Sample Conditions 
4.1.1. Specimen Collection Procedures 
Sample collection procedures are summarised in Table 4.1.  
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Table 4.1: Summary of sample collection procedures 
Volume required per assay: Five, 50 µl whole blood aliquots spotted onto filter paper 
(Whatman - Protein Saver 903 Card) 
Matrix: Human Whole Blood 
Anticoagulant used:  K3EDTA 
Stability concerns:  TFV-DP is prone to dephosphorisation. Therefore, whole blood 
samples must be kept on ice until spotting on filter paper. 
Sample preparation 
considerations:  
A calibrated pipette must be used to accurately aliquot 50 µl of 
whole blood from the collection tube and spot it onto the pre-
marked circles on the filter paper (Whatman-Protein Saver 903 
Card). The filter paper sample must be left at room temperature 
for two hours to dry and subsequently placed into a resealable 
bag with desiccant. The bag must be sealed and stored at 
approximately -80⁰C. 
Conditions pertaining to the 
rejection of samples: 
 
Insufficient sample volume blood spot or smeared blood spot  
Temperature inconsistencies 
Undue exposure to light 
Anticoagulant confusion (K2EDTA has been shown to have 
minimal anticoagulant matrix effects) 
Unsure sample identity 
Other conditions at the direction of the laboratory principal 
investigator, which would make sample analysis impossible. 
 
4.1.2. Summary of stability data for TFV-DP 
Information regarding the stability of the analyte of interest is essential for the correct storage and handling of 
samples during the analytical process. A summary of the stability data of TFV-DP is discussed in Table 4.2 below. 
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Table 4.2: TFV-DP stability data 
Stability 
Stability in Matrix (at ~-20°C) 
TFV-DP has been shown to be stable in DBS for at least 198 days when 
stored at approximately -20°C. 
Stability in Matrix (at ~4°C) TFV-DP is stable in DBS for up to 14 days when stored at ~4°C. 
Stability in Matrix (at RT) 
TFV-DP is stable in DBS for at up to 7 days when stored at room 
temperature. 
Stability in Matrix (at ~37°C) TFV-DP is NOT stable in DBS when stored at ~37°C for up to six days. 
Stock Solution Stability 
(methanol) 
Stock solutions of TFV-DP in methanol were found to be stable when 
stored at ~-80°C for at least 150 days, and for ~24 hours when stored at 
room temperature, ~4°C, ~-20°C.  
Stock solutions of TFV in methanol were found to be stable when stored at 
~-80°C for at least 330 days, and for ~24 hours when stored at room 
temperature, ~4°C, ~-20°C.  
Working Solution Stability 
(water) 
Working solutions of TFV-DP in water were found to be stable when stored 
at room temperature, ~4°C, ~-20°C and ~-80°C for ~4 hours and stable at 
~-20°C and ~-80°C only when stored for 24 hours. 
Working solutions of TFV in water were found to be stable when stored at 
room temperature, ~4°C and ~-80°C for ~24 hours, and at ~-20°C for 20 
days. 
Freeze and Thaw Stability 
TFV-DP was found to be stable in DBS when subjected to three freeze-
thaw cycles. 
Stability in whole blood TFV-DP is not stable in whole blood when stored at room temperature. 
Benchtop stability TFV-DP was found to be stable in a DBS for up to 12 hours in ambient light 
at room temperature.   
Reinjection reproducibility 
TFV-DP is stable and can be reinjected up to five days after extraction, if 
samples are stored at ~4°C. 
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4.2. Method description 
4.2.1.TFV-DP 
Information regarding the TFV-DP analytical reference standard, used during the validation of the method, is 
shown in Table 4.3. 
Table 4.3: TFV-DP analytical reference standard properties 
Name: TFV-DP 
Analytical Reference 
standard:  
Tenofovir-Diphosphate Tetraammonium Salt 
Synonyms:  PMPApp Triethylamine Salt, Diphosphoric Acid Triethylamine Salt 
Molecular Formula: C9H16N5O10P3•x(C6H15N) 
Molecular formula of free 
acid/base: 
C9H16N5O10P3 
Molecular Weight:  515.29 Free acid/base:  447.17  Exact Mass: 447.01 
Chemical structure:  
    
In-house catalogue number  543/544 
Manufacturer: Moravek 
Lot No. M-1731 
Purity  95.7% Adjustment made? YES NO 
Expiry date: Sept 2018 (retest) 
 
4.2.2. ISTD: TFV-DP Adenine-13C5 
Information regarding the deuterated internal standard is summarised in Table 4.4. 
Table 4.4: Internal standard analytical reference standard 
Name: TFV-DP -13C5 
Analytical Reference 
standard:  
TFV-DP, tetraammonium salt, adenine -13C5 
Synonyms:  None 
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Molecular Formula: C15H31N6O10P3•x(C16H36N) 
Molecular formula of free 
acid/base: 
C15H31N6O10P3 – The reference standard comes as a 2 µmol powder and 
therefore no correction was made.  
Molecular Weight:  520.26 Free acid/base:  452.14 g/mol 
Chemical structure:  
  
In-house catalogue number  551 
Manufacturer: Moravek 
Lot No. MG-135 
Purity  96.0% Adjustment made? YES NO 
Expiry date: No expiry date on COA 
 
4.3. Biological matrix 
The method was designed for the analysis of DBS consisting of 50 µl of whole blood spotted onto filter paper. 
Information regarding the biological matrix used in the validation of the method is summarised in Table 4.5. 
Table 4.5: Summary of the biological matrix information used in validation 
Identity:  Whole Blood 
Anticoagulant:  K3EDTA 
Source (including internal reference): Inhouse donation 
 
4.4. Solution preparations 
4.4.1. Stock Solution Preparation 
Stock solutions (SS) were prepared by weighing a mass of the analyte into a container and dissolving the weighed-
out mass in the desired volume of water to obtain target concentrations of 1000 μg/ml. The weighed mass of the 
analyte was also adjusted where applicable (purity, salt, etc.). All stock solutions were stored at approximately -
80°C until required. Stock solutions were used to prepare working solutions or to spike blank biological matrix as 
required. The ISTD stock solution (ISS1) was made by dissolving 2.00 µmol of isotopically labelled TFV-DP 
(adenine 13C5) in 1.00 ml of water, with the use of a calibrated pipette to prepare a 2.00 µmol/ml stock solution. 
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This was subsequently aliquoted and stored at approximately -80°C until required. A summary of the TFV-DP 
stock solution preparations (SS1 & SS2) are shown in Tables 4.6 and 4.7. The preparation of the TFV-DP ISTD 
(ISS1) is shown in Table 4.8. 
 
Table 4.6: Preparation of TFV-DP stock solution (SS1) 
Solvent  Volume Weighed Adjusted* SS1 
used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Water 0.648  0.780 0.648  1000  
* Reason for Adjustment (e.g. purity, salt, hydrate): Purity 95.7%; Tetraammonium salt 
* Calculation: = 0.780 x 0.957 x 447.173/515.297 
 
Table 4.7: Preparation of TFV-DP stock solution (SS2) 
Solvent  Volume Weighed Adjusted* SS2 
used solvent mass of analyte mass of analyte concentration 
  (ml) (mg) (mg) (µg/ml) 
Methanol 0.681  0.820  0.681  1000  
* Reason for Adjustment (eg. purity, salt, hydrate): Purity 95.7%; Tetraammonium salt 
* Calculation: = 0.820 x 0.957 x 447.173/515.297 
 
Table 4.8: Preparation of 13C5 TFV-DP ISTD stock solution (ISS1) 
Solvent  
used 
Volume  
Solvent 
 (ml) 
Moles 
 (µmol) 
Adjusted* 
Mass of analyte 
(µmol) 
ISS1 
 Concentration 
 (µmol/ml) 
Water 1.00 2.00 2.00 2.00 
 
* No adjustment was made 
 
4.4.2. Preparation of ISTD Working Solutions 
ISTD working solution (IWS1) was prepared daily by spiking 10.0 μl of ISS1 stock solution into 0.990 ml water. An 
aliquot of this solution was added to the lysate solution to achieve a final ISTD concentration equivalent to 500 
fmol/ punch in the lysate. 
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4.4.3. Preparation of TFV-DP Calibration Standards Working Solutions 
Calibration standard working solutions (WS) were prepared volumetrically in water by spiking 10.0 μl of TFV-DP 
stock solution (SS1) into 9.99 ml of water to make Stock A. A volume of 0.668 ml of Stock A was subsequently 
added to 4.00 ml of water, using a calibrated pipette. This was then serially diluted with water to attain the desired 
working solutions as presented in Table 4.9. The working solutions were kept on ice until storage or spiking. 
Multiple 80 μl aliquots of each working solution were stored in individual 1.5 ml Eppendorf tubes at approximately 
-80°C. Literature has shown the stability of TFV-DP in water for at least two months, when stored at approximately 
-80°C 77.  
 
Table 4.9: Preparation of TFV-DP Calibration Standards Working Solutions 
Standard 
Blank 
Water 
Volume 
(ml) 
Volume 
SS1 
spiked 
(µl) 
Dilution 
Source 
Dilution 
Source 
Volume (ml) 
Total 
Volume 
of 
Dilution 
(ml) 
TFV-DP spiking solution conc. 
(pg/ml) (pmol/ml) (fmol/punch) 
Stock A 9.99  10.0     10.0 1000000 2236 44726 
WS1 4.00    Stock A 0.668 4.67 143102 320 6400 
WS2 2.00    WS1 2.00 4.00 71551 160 3200 
WS3 2.00    WS2 2.00 4.00 35775 80.0 1600 
WS4 2.00    WS3 2.00 4.00 17888 40.0 800 
WS5 2.00    WS4 2.00 4.00 8944 20.0 400 
WS6 2.00    WS5 2.00 4.00 4472 10.0 200 
WS7 2.00    WS6 2.00 4.00 2236 5.00 100 
WS8 2.00    WS7 2.00 4.00 1118 2.50 50.0 
 
 
4.4.4. Preparation of TFV-DP Quality Controls Working Solutions  
QC working solutions (WSs) were prepared in water by adding a volume of 10.0 μl of TFV-DP stock solution (SS2) 
to 9.99 ml of water to make Stock B. A volume of 1.11 ml of Stock B was subsequently added to 3.39 ml of water, 
using a calibrated pipette.  This was subsequently diluted with water to attain the desired working solutions as 
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presented in Table 4.10. Multiple 80 μl aliquots of each working solution were stored in individual 1.5 ml Eppendorf 
tubes at approximately -80°C.  
 
Table 4.10: Preparation of TFV-DP QC Working Solutions 
Quality control 
Blank 
Water 
Volume 
(ml) 
Volume 
SS2 
spiked 
(µl) 
Dilution 
Source 
Dilution 
Source 
Volume 
(ml) 
Total 
Volume 
of 
Dilution 
(ml) 
TNF-DP spiking solution conc. 
(pg/ml) (pmol/ml) (fmol/punch) 
Stock B 9.99  10.0     10.0 1000000 2236 44726 
QCDil 3.39    Stock B 1.11 4.50 245945 550 11000 
QC H 2.30    QC Dil 2.00 4.30 114473 256 5120 
QC M 2.00    QC H 2.00 4.00 57237 128 2560 
SYS 6.53    QC M 2.00 8.53 13420 30.0 600 
QC L 6.00    SYS 2.00 8.00 3355 7.50 150 
LLOQ 4.00    QC L 2.00 6.00 1118 2.50 50.0 
 
*The QC Dilute sample is used to qualify the dilution process in the first validation batch and is not included in 
subsequent validation or sample batches 
 
4.4.5. Verification of Standards and Quality Controls 
The calibration standards (STDs) and QC samples were analysed in a batch prior to sample analysis to confirm 
their accuracy. A second stock solution was prepared independently by another analyst and used to verify the 
stock solution used for the preparation of STDs and QCs. Prior to sample analysis, QC working solutions was 
analysed against freshly prepared calibration standard working solutions to verify their accuracy and to determine 
stability at ~-80°C. Should this verification meet the acceptance criteria, the curve was deemed valid for sample 
analysis and the validation purposes. Verified standards and QCs were stored as batches. 
 
4.4.6. Buffers and Solutions 
The constituents and preparation of the necessary solutions are described below. As with the stock solutions and 
STDs and QCs, the specific stability of the solutions were determined and the solutions were replaced after the 
expiry date.  
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- Mobile Phase A: Add 0.771 g ammonium acetate to 300 ml acetonitrile and 700 ml water (10.0 mM), 
adjust pH by adding 200 µl of acetic acid (pH 5.9). Keep at room temperature and replace after five days. 
- Mobile Phase B: Add 0.154 g ammonium acetate to 300 ml acetonitrile and 700 ml water (2.00 mM), 
adjust pH by adding 2.00 ml ammonium hydroxide (pH 10.1). Keep at room temperature and replace after 
five days. 
- Autosampler needle wash: Add 0.385 g ammonium acetate to 100 ml acetonitrile and 900 ml water, 
adjust pH by adding 0.500 ml ammonium hydroxide (pH 9.0). Keep at room temperature and replace after 
one month. 
- Lysate: Add 300 ml of water to 700 ml of methanol. Store at ~4°C and replace after two weeks. 
 
4.5. Extraction procedure 
This section lists the extraction protocol, which is used for the analysis of analytical batches. However, prior to the 
discussing the extraction protocol, it is important to define what an analytical batch is and what it consists of.  
 
4.5.1. Criteria for an Analytical Batch 
An analytical batch is a single extraction procedure applied to a series of unknown samples, which must include a 
system suitability sample (SYS) of sufficient volume to inject at least ten times, a minimum of eight STDs analysed 
in duplicate, three levels of QCs analysed in duplicate, a blank and a double blank sample. These are all required 
to assess various parameters, including accuracy, precision, carryover and system suitability, in order to ensure 
the validity of the results. STDs are spread throughout the run, in order to capture instrument drift. QC samples 
are also spread over the run, in order to control the analysis appropriately. Blanks and double blanks are run after 
the highest calibration standard, consecutively in order to ascertain the level of carryover for the batch. 
 
4.5.2. Extraction Methodology 
Preceding the extraction procedure of analytical batches, the appropriate DBS cards were removed from their 
storage at -80°C, and subsequently placed at room temperature for approximately 20 minutes. Three, 3 mm 
punches were made within the designated circle on the Whatman Protein Saver 903 Cards containing the DBS. 
The 3 mm punches were then placed in 1.5 ml Eppendorf tubes. The same procedure was followed for the sample 
preparation of STD, QC, blank, and double blank samples; however, the DBS used for these samples were 
prepared with blank whole blood. 
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The ISTD stock solution (ISS1) was used to make a fresh ISTD working solution (IWS1), which was subsequently 
added to the lysate to achieve a concentration of 500 fmol/punch as outlined in Section 4.4.2. A volume of 500 µl 
lysate, containing ISTD, was added to each of the 1.5 ml Eppendorf tubes containing the three 3 mm DBS punches. 
All samples received 500 µl of the lysate with ISTD except for the double blank, which received ISTD-free lysate. 
To reach the desired concentration in the STD and QC samples a volume of 60 µl of each STD and QC working 
solution level was added to their respective samples. To compensate for the added volume in the STD and QC 
tubes, 60 µl of water was added to all unknown, blank and double blank samples.  
After the sample preparation was completed, the Eppendorf tubes were placed into an ultrasonic bath (Instrulab®), 
set at room temperature, and sonicated for 10 minutes at room temperature. The samples were subsequently 
removed from the ultrasonic bath, before being aliquoted into Phree™ phospholipid removal cartridges. However, 
the Phree™ cartridges had to be conditioned before samples could be added and this was done by adding 1 ml 
of methanol to each cartridge and subsequently eluting the methanol into a waste container. The Phree™ columns 
were placed into a SPEEDISK® 48 SPE positive pressure system to aid in the elution of the samples and other 
solutions. A volume of 500 µl of lysate was removed from each sample with a calibrated pipette and added to the 
Phree™ cartridge, while taking care not to remove the 3 mm DBS punches. The lysate was eluted into disposable 
borosilicate glass tubes, which were subsequently placed in a Stuart® Evaporator with a heating block. The extract 
was left under a gentle stream of nitrogen at 40⁰C for 30 minutes to evaporate. After the samples had evaporated, 
they were reconstituted with 150 µl of water. To ensure the complete reconstitution of the samples, each 
borosilicate glass tube was vortexed for 30 seconds before being transferred to a 96-well plate. 
 
4.6. Instrument Setup and Special Precautions 
The following alterations were made to the LC-MS/MS system to ensure the accuracy and reliability of the 
analytical method. A custom injection program, as outlined in Section 4.8, was used to help prevent carry-over.  
Each sample injection was followed by two subsequent wash steps, which consisted of a 20 µl injection of mobile 
phase B. The gradient flow schedules of each of the methods are summarised in Section 4.8. All post autosampler 
stainless steel tubing was replaced with Peek tubing and the column switching valve was bypassed. A post-column 
mobile phase split (1:5) was also included at the source.  
 
4.7. Reagents, Chemicals, Consumables, and Equipment Used 
The specific chemicals and reagents, consumables and equipment that were used for this method are summarised 
in Tables 4.11, 4.12 and 4.13, respectively. 
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Table 4.11: Chemicals and reagents 
Reagent Catalogue No. Grade Supplier 
Acetic Acid 49199-50ml F LC/MS Sigma-Aldrich 
Acetonitrile LC015-2.5 LC/MS Anatech  
Ammonium Acetate 431311#50g ACS Sigma-Aldrich 
Ammonium Hydroxide  338818-100ML ACS Sigma-Aldrich 
Methanol LC230-2.5 LC/MS Anatech 
Water In house Millipore 18.2 mὨ.cm @ 25°C N/A 
TFV-DP M-1731 95.7% Moravek  
TFV-DP, tetraammonium salt, adenine -13C5  MG-135 96.0% Moravek 
 
 
Table 4.12: List of required consumables 
Description Catalogue No. Supplier 
96 well plate 5042-1385 Agilent Technologies 
Sealing mats  PAXG AN-2ml-RD-PK Lasec SA 
Pipette tips (White) 771290 Lasec SA 
Pipette tips (Yellow) P2TIP018Y-010200R Lasec SA 
Pipette tips (Blue) P2TIP018B-001000R Lasec SA 
Borosilicate Culture Tubes (Kimble) Item 1505(12 x 75) Lasec SA 
Filter Paper: Protein Saver 903 Card 10531018 Whatman 
Phree Phospholipids Removal columns (1 ml) 8B-S133-TAK Phenomonex 
Analytical column: BioBasic AX, 5µm, 50 x 2.1 mm 73105-052130 ThermoFisher Scientific 
 
Table 4.13: Equipment 
Name Model Manufacturer 
Pipette 2-20 µl Various 
Pipette 20-200 µl Various 
Pipette 200-1000 µl Various 
Vortex Genie 2 Scientific Industries 
Analytical Microbalance CPA2P Sartorius 
SPEEDISK 48 SPE positive pressure system  48 SPE Speedisk 
Evaporator with heating block (incubator) SBH 130D/3 Stuart 
Ultrasonic Bath UMC5 Instrulab 
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4.8. Mass Spectrometer and Chromatographic Conditions 
Important details concerning the LC-MS/MS system and the parameters that were used during the analysis of 
samples during the validation process are summarised in Table 4.14. This includes the various mobile phases and 
their constituents and the custom injection program. These parameters are strictly adhered to during the validation 
process and any analysis of samples that follow. 
 
Table 4.14: A summary of the instrument and chromatographic conditions 
Instrument used AB Sciex 5500 Qtrap 
Project number TFV-DP 2016/174 
Acquisition method Acquisition method: LO_Anion Exchange_20ul.dam 
Wash run A: LO_Anion Exchange_wash AI.dam 
Wash run B: LO_ Anion Exchange_wash B.dam 
Analytical Column Analytical column: BioBasic AX, 5µm, 50 x 2.1 mm 
Column Temperature ~30⁰C 
Mobile Phase The run contains a gradient consisting of the two mobile phases:  
-A mixture of 10.0 mM ammonium acetate in water and acetonitrile 
(70:30, v/v), adjusted to pH 5.9 by adding acetic acid. 
-A mixture of 2.00 mM ammonium acetate in water and acetonitrile 
(70:30, v/v), adjusted to pH 10.1 by adding ammonium hydroxide. 
 
Analytical Run: LO_Anion Exchange_20ul.dam 
Total Time (min) Flow Rate (µl/min) Line A (%) Line B 
(%) 
0.00 700 100 0 
0.40 700 50 50 
1.10 700 50 50 
1.20 700 5 95 
2.40 700 5 95 
2.60 700 100 0 
3.50 700 100 0 
 
Wash run 1: LO_Anion Exchange_wash A.dam 
Total Time (min) Flow Rate (µl/min) Line A (%) Line B 
(%) 
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0.00 700 5 95 
1.00 700 5 95 
1.10 700 100 0 
 
Wash run 2: LO_ Anion Exchange_wash B.dam 
Total Time (min) Flow Rate (µl/min) Line A (%) Line B 
(%) 
0.00 700 5 95 
0.50 700 5 95 
0.65 700 100 0 
3.50 700 100 0 
 
  
Pump type Agilent 1260 Binary Pump 
Flow Rate 0.700 ml/min 
Autosampler Type Agilent 1260 High Performance Autosampler 
Sample arrangement  96-well plate 
Injection volume 20 μl 
Autosampler 
Temperature 
~8°C 
Custom injection 
program 
DRAW def. amount from sample, def. speed, def. offset 
WASH NEEDLE with default wash parameters 
INJECT 
REMOTE start pulse, duration 60*12.5 msec 
WAIT 3.3 min  
VALVE bypass 
WAIT 0.50 min  
VALVE mainpass 
VALVE bypass 
VALVE mainpass 
REMOTE start pulse duration 120*12.5 msec 
 
4.9. System Suitability Requirements 
As has been discussed in Section 4.5, the system suitability test must be done before each analytical batch. A 
SYS, consisting of a mid-level extracted sample, is injected a minimum of 10 times. The acceptance criteria for 
system suitability tests requires the percentage covariance (CV(%)) of the last six injected sample peak area ratios 
to be ≤ 5%. All SYS samples are injected with the LO_ Anion Exchange_SYS_10ul.dam method, which is identical 
 81 
 
to LO_Anion Exchange_20ul.dam (shown in Table 4.14); however, the injection volume is only 10 µl. The lower 
injection volume is used to allow more injections per extracted SYS sample. 
4.10. Detection Details 
The various instrument settings pertaining to the detection of the analyte of interest are summarised in Tables 
4.15 to 4.18. 
Table 4.15: Detection settings 
Mass spectrometer Identity API 5500 QTrap 
APCI/ESI ESI 
 
 
Table 4.16: Electro Spray Ionisation Settings 
Nebuliser gas (Gas 1) (arbitrary unit) 40 
Turbo gas (Gas 2) (arbitrary unit) 70 
CUR (curtain gas) (arbitrary unit) 50 
CAD (collision gas) (arbitrary unit) 2 
TEM (Source Temperature) (°C) 500 
IS (Ion Spray Voltage) (V) 4500 
 
 
Table 4.17: MS/MS Settings 
 TFV-DP ISTD 
Protonated molecular ion mass (m/z) [M+H]+ 448.0 452.9 
Product ion mass (m/z) Quantifier 350.0 354.9 
Product ion mass (m/z) Qualifier 270.1 274.9 
Dwell time (ms) 150 150 
Declustering potential (V) 136 151 
Entrance potential (V) 10 10 
Collision energy (eV) 23 23 
Collision cell exit potential (V) 28 26 
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Table 4.18: Scan description 
Scan Type MRM 
Polarity Positive 
Pause time (msec) 5 
 
4.11. Analyte Spectra 
The mass spectra of the analyte of interest and the ISTD are show in this section. Both were observed after 
infusing a solution of 200 ng/ml of each analyte in the into an AB Sciex 55000 mass spectrometer using a Hamilton 
syringe set at a constant flow rate of 10 µl/min. 
 
4.11.1 Analyte: TFV-DP 
A mass spectrum of the analyte after collision-induced dissociation in the fragmentation cell, showing the TFV-DP 
precursor ion at m/z 448 as well as the product ions, Figure 4.1. 
 
 
Figure 4.1: Mass spectrum of TFV-DP. 
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4.11.2. ISTD: TFV-DP, Adenine-13C5 
A mass spectrum of the analyte after collision-induced dissociation in the fragmentation cell, showing the TFV-
DP-ISTD precursor ion at m/z 453 as well as the product ions, Figure 4.2.  
 
Figure 4.2: Mass spectrum of ISTD. 
  
4.12. Recording and integration 
4.12.1 Quantitation Parameters, Ions Monitored, and Retention Times:  
Analyte concentrations were calculated using Analyst software with the Analyst Classic Algorithm. Duplicate 
calibration points were used to construct the calibration curve, using the validated regression model (fit type and 
weighting). Important information regarding the quantitation of both TFV and the ISTD is summarised in Tables 
4.19 to 4.21 below. 
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Table 4.19: Summary of the quantitation parameters 
 Analyte: TFV-DP ISTD: TFV-DP (adenine -13C5) 
Software Version Analyst 1.6.2 using Analyst Classic Algorithm 
Algorithm Analyst Classic 
Calibration fit type Quadratic Quadratic 
Parameter Area Ratio Area Ratio 
Curve Weighting  1/x 
Bunching Factor 1 1 
Number of smooths 2 2 
 
Table 4.20: Precursor and Product ions monitored 
 Precursor Ion Mass 
(amu) 
Product Ion Mass (amu) 
Analyte: TFV-DP 448.0 350.0 
ISTD: TFV-DP (adenine -13C5) 452.9 354.9 
 
 
Table 4.21: Retention time of the analytes in minutes 
Analyte: TFV-DP 2.72 
ISTD: TFV-DP (adenine -13C5) 2.71 
  
4.13. Acceptance criteria 
To ensure the validity of the results obtained from the developed method, any analytical batch results must undergo 
a quality review procedure and meet the various acceptance criteria that are required for the STDs, QC’s, blanks 
and double blanks. The review process and acceptance criteria are discussed below. 
4.13.1. Quality Review Procedure 
All data is subjected to a QC review by a designated analyst. This review considers the acceptance criteria listed 
below, as well as appropriate scientific criteria for data acceptance. Following the completion of a project, the 
project documentation is reviewed by Quality Assurance to confirm standard operating procedure compliance and 
regulatory adherence if applicable. This includes a complete data audit to ensure that the data is accurately 
reported in the dataset to be released. Following this, the data may be released.  
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4.13.2. Calibration Standards  
Seventy five percent of the standards used must fall within 15% of the nominal concentration (i.e. 85–115%), 
except for the LLOQ, which should be within 20% (i.e. 80–120%) of the nominal value. Duplicate points are used 
to construct the calibration curve. Failed points must be excluded from the calibration curve’s regression 
determination.  
 
4.13.3. Quality Control  
A minimum of 6 QC levels covering the range from ~80% of the ULOQ to within three times the LLOQ are injected 
in each analytical batch. Sixty seven percent of all controls assayed must meet the acceptance criteria of 85–
115% accuracy. The allowed failures may not be of the same concentration, therefore 50% of controls run at every 
level must pass. Failure to meet these acceptance criteria will require the reanalysis of the unknown samples. The 
number of QC samples included in an analytical assay run must be ≥ 5% of the unknown samples in each run.  
 
4.13.4. Blanks and Double Blanks 
Blanks and double blanks are used to assess the carryover during an analytical batch. Blanks and double blanks 
are analysed immediately after the highest calibration standard. The double blank is injected first followed by a 
blank sample, in order to determine any possible interference caused by the ISTD. The observed peak areas of 
the analyte and ISTD in the blank and double blank samples should be less than 20% of the peak areas observed 
in the LLOQ samples.  
 
4.13.5. Duplicate and Triplicate Analyses  
Unknown samples are analysed singly. Without evidence to show that the analytical batch has failed, these results 
are accepted. When repeating a selected sample due to suspected experimental error, the sample is repeated in 
duplicate. The average of the repeat values is selected over the original value only if a >15% difference between 
the average of the repeat values and the original value is observed, otherwise the original value stands. When 
repeating a batch of samples due to a failed analytical batch or when assaying dilution requests, samples are 
repeated singly.  
 
4.13.6. Peak Reintegration  
As far as possible, method development ensures that reintegrations are not routinely necessary for an assay. 
Automatic reintegration is preferable, using a sample chromatogram from the run, should the analyst deem it 
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necessary to adjust the integration parameters for a batch. Chromatograms are reviewed as part of the batch 
acceptance procedure. The original data may not be overwritten, and the reintegrated chromatogram is saved 
separately and printed along with the entire chromatogram set. The reintegrations are reviewed by QC and quality 
assurance prior to data release. 
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Chapter 5: Method Validation 
 
This chapter describes the validation process of the bioanalytical method, described in Chapter 4. The validation 
was carried out in accordance to FDA and EMA guidelines for the validation of a bioanalytical assay 95,96. The 
validation process must be completed before the implementation of any bioanalytical method and is done to 
demonstrate the reliability and suitability of an assay for its intended use. This chapter will discuss and summarise 
the various validation experiments and their accompanying results. 
According to the FDA and EMA, the validation of a bioanalytical method has to be completed to objectively 
demonstrate and document the accuracy, precision, specificity, sensitivity, and reproducibility of a bioanalytical 
method 95,96. During the validation process, stability experiments are also completed to determine the stability of 
the analyte for the optimal storage, handling and processing of samples of unknown concentrations. 
Demonstrating acceptable within- and between-day accuracy and precision over the desired calibration range is 
an essential step in demonstrating the robustness and reproducibility of the bioanalytical method. In order to do 
so, a set of calibration STDs and QCs were prepared and assayed in three consecutive runs of which at least two 
were on different days. A full set of STDs and QCs were prepared and stored at -80˚C, as outlined in Chapter 4. 
The required aliquots were removed from storage and subsequently thawed and assayed according to the method 
described in Chapter 4. Each run consisted of a duplicate of each STD level, in order to produce a calibration 
curve. This would be accompanied by six replicates of each of the QC levels. 
 
5.1. Procedure 
To demonstrate acceptable within- and between-day accuracy and precision over the desired concentration range, 
STDs and QCs were prepared and assayed in three consecutive runs. A full set of STDs and QCs were prepared 
and stored frozen (at ~-80˚C), and the required aliquots were thawed and assayed.  Each run consisted of all the 
STDs in duplicate to produce one calibration curve and six replicates of the prepared QCs. A QC spiked to a 
concentration above the ULOQ was diluted (1:4) with blank plasma to validate the dilution of samples for which 
the concentrations potentially do not fall within the validated range. 
Standard curve fitting was determined by applying the simplest model that adequately describes the concentration-
response relationship using appropriate weighting and statistical tests for goodness of fit. A calibration curve based 
on a well-selected regression model must consist of between six and eight calibration levels covering the entire 
calibration range from the LLOQ to the ULOQ. The regression model selected during the validation is used for the 
quantification of the study samples. In the case of a re-instatement (or partial) validation, the regression model 
that was used for the full validation must be used for the re-instatement validation and the processing of unknown 
samples. 
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5.2. Stock solutions, STD and QC Preparation 
The preparation of stock solutions, STDs and QCs were described in Section 4.4 in Chapter 4 and this was strictly 
adhered to during the validation process. All stock solutions, STDs and QCs were stored at ~-80⁰C until required.  
 
5.3. Validation Results 
Acceptance criteria:  Accuracy is expressed as the concentration of analyte found as a percentage of the nominal 
concentration (%Accuracy), while precision is expressed as CV(%) seen in a batch of assays.   
The calculated calibration curve should fit the plot of measured responses vs. nominal concentrations of the STDs 
adequately; giving a r2 fit parameter of as close to one as possible. 
For a valid method the within- and between-batch accuracy is required to be within 15% (i.e. %Accuracy should 
be between 85–115%) over the entire calibration range and within 20% of nominal concentration at the LLOQ.  
For a valid method the within- and between-batch precision is required to be less than 15% (i.e. CV(%) should be 
less than 15%) over the entire calibration range and less than 20% at the LLOQ. Duplicate STDs are analysed at 
each calibration point. Each STD is used to define the calibration equation, unless one of those points does not 
meet the above criteria. In this instance, the invalid point would be excluded and only a single STD would be used 
at that level. This allows for a single STD to fail at either the LLOQ or the ULOQ without influencing the resulting 
calibration range.  
 
5.4. Validation 1 (Day 1) 
Within-batch accuracy and precision were assessed by assaying all the STDs in duplicate, to produce one 
calibration curve, and six replicates of each QC level in a single batch of assays. The within-batch accuracy and 
precision of the assay procedure were assessed by calculating the regression equation and constructing the 
calibration curve based on peak area ratios of analyte to ISTD. 
 
5.4.1. Validation 1, Day 1 
The calibration curve is presented in Figure 5.1. The regression equation used was Quadratic (weighted by 1/x 
concentration), f(x) = a + bx + cx2, Table 5.1. A summary of the STD and QC results of validation batch one is 
presented in Tables 5.2 and 5.3. 
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Figure 5.1: Representative calibration curve for TFV-DP: Validation batch one, day one. r =0.999. 
 
Table 5.1: Regression equation for TFV-DP validation batch one, day one 
Validation  Quadratic Calibration Curve Parameters 
Batch a B c r 
1 -0.00000000282 0.000301 -0.00465 0.999 
 
Table 5.2: Summary of accuracy and precision results for the STDs of validation batch one 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 (LLOQ) 50.0 58.0 1.59 2.7 116.1 2 of 2 
S7 100 97.8 0.554 0.6 97.8 2 of 2 
S6 200 192 11.8 6.2 96.2 2 of 2 
S5 400 369 1.00 0.3 92.1 2 of 2 
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S4 800 733 26.0 3.5 91.7 2 of 2 
S3 1600 1680 21.1 1.3 105.0 2 of 2 
S2 3200 3254 36.0 1.1 101.7 2 of 2 
S1 6400 6365 449 7.1 99.4 2 of 2 
 
 
Table 5.3: Summary of accuracy and precision results of the QCs of validation batch one 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
LLOQ 50.0 54.2 3.81 7.0 108.5 6 of 6 
QC L 150 151 6.40 4.2 100.7 6 of 6 
QC M 2560 2515 187 7.4 98.2 6 of 6 
QC H 5120 5221 160 3.1 102.0 
6 of 
6 
 
5.5. Validation 2 and 3 
Between-batch accuracy and precision were determined by assaying two additional separate consecutive batches, 
each consisting of a double set of STDs designated for use in the assay of samples of unknown concentrations 
and six replicates of each of the QCs. The between-batch accuracy and precision of the assay procedure were 
assessed by constructing a calibration curve based on analyte/ISTD peak area ratios and calculating the 
regression equations. 
 
5.5.1. Validation 2, Day 2 
The calibration curve for validation batch two is presented in Figure 5.2. The regression equation used was 
Quadratic (weighted by 1/x concentration), f(x) = a + bx + cx2, as presented in Table 5.4. A summary of the STD 
and QC results of validation batch two is presented in Tables 5.5 and 5.6. 
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Figure 5.2: Representative calibration curve for TFV-DP: Validation batch two, day two. r =0.997. 
 
Table 5.4: Regression equation for TFV-DP validation batch two, day two 
Validation  Quadratic Calibration Curve Parameters 
Batch a B c r 
2 -0.00000000572 0.000321 -0.00683 0.997 
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Table 5.5: Summary of accuracy and precision results of the STDs of validation batch two 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 50.0 55.4 5.23 9.4 110.8 2 of 2 
S7 100 105 4.82 4.6 105.0 2 of 2 
S6 200 192 10.8 5.6 95.8 2 of 2 
S5 400 356 7.04 2.0 89.0 2 of 2 
S4 800 759 3.81 0.5 94.8 2 of 2 
S3 1600 1642 56.7 3.5 102.6 2 of 2 
S2 3200 3281 32.6 1.0 102.5 2 of 2 
S1 6400 6359 173 2.7 99.4 2 of 2 
 
 
Table 5.6: Summary of the accuracy and precision results of the QCs of validation batch two 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
QC LLOQ 50.0 60.0 4.07 6.8 120.0 6 of 6 
QC L 150 158 12.1 7.6 105.5 6 of 6 
QC M 2560 2662 44.8 1.7 104.0 6 of 6 
QC H 5120 5237 216 4.1 102.3 6 of 6 
 
 
 
 93 
 
5.5.2. Validation 3, Day 3 
The calibration curve for validation batch three is presented in Figure 5.3. The regression equation used was 
Quadratic (weighted by 1/x concentration), f(x) = a + bx + cx2, as presented in Table 5.7. A summary of the STD 
and QC results of validation batch three is presented in Tables 5.8 and 5.9. 
 
 
Figure 5.3: Representative calibration curve for TFV-DP: Validation batch three, day three. r =0.999. 
 
 
Table 5.7: Regression equation for TFV-DP validation batch three, day three 
Validation  Quadratic Calibration Curve Parameters 
Batch a B c r 
3 -0.00000000705 0.000564 -0.00974 0.999 
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Table 5.8: Summary of the accuracy and precision results of the STDs of validation batch three 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 50.0 58.1 2.14 3.7 116.1 2 of 2 
S7 100 95.4 3.67 3.8 95.4 2 of 2 
S6 200 200 2.97 1.5 100.1 2 of 2 
S5 400 366 7.89 2.2 91.4 2 of 2 
S4 800 745 16.1 2.2 93.1 2 of 2 
S3 1600 1612 18.3 1.1 100.7 2 of 2 
S2 3200 3327 179 5.4 104.0 2 of 2 
S1 6400 6346 170 2.7 99.1 2 of 2 
 
 
Table 5.9: Summary of the accuracy and precision results of the QCs of Validation batch three 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
QC LLOQ 50.0 57.0 3.48 6.1 114.0 6 of 6 
QC L 150 153 4.90 3.2 101.8 6 of 6 
QC M 2560 2464 35.4 1.4 96.3 6 of 6 
QC H 5120 4951 87.1 1.8 96.7 
6 of 
6 
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5.6. Summary of the Combined STD and Quality Control Results 
The overall accuracy and precision of the assay procedure is assessed by calculating the accuracy and precision 
statistics over the within- and between-batch validation batches (three in total). Accuracy is expressed as the 
concentration of the analyte found as a percentage of the nominal concentration (%Accuracy), while precision is 
expressed as the CV(%). The combined regression, STDs and QCs results (all three validation batches) of TFV-
DP are summarised in Tables 5.10 to 5.12 below.   
 
 
Table 5.10: Overall Summary of Calibration Curve Parameters 
Validation  Quadratic Calibration Curve Parameters 
Batch a B c r 
1 -0.00000000282 0.000301 -0.00465 0.999 
2 -0.00000000572 0.000321 -0.00683 0.997 
3 -0.00000000705 0.00564 -0.00974 0.999 
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Table 5.11: Summary of the three validation batches STD results 
 
Validation Batch 
Sample ID STD 1 - ULOQ STD 2 STD 3 STD 4 STD 5 STD 6 STD 7 STD 8 - LLOQ 
Nominal 
Conc. 
6400 3200 1600 800 400 200 100 50.0 
  
(fmol/ 
punch) 
(fmol/ 
punch) 
(fmol/ 
punch) 
(fmol/ punch) (fmol/ punch) (fmol/ punch) (fmol/ punch) 
(fmol/ 
punch) 
Replicates Observed Conc. Observed Conc. Observed Conc. Observed Conc. Observed Conc. Observed Conc. Observed Conc. Observed Conc. 
Validation 1  1 6050 3280 1690 715 369 184 97.4 59.2 
  2 6680 3230 1660 752 368 201 98.2 56.9 
Validation 2  1 6490 3310 1610 762 344 182 110 60.1 
  2 6220 3250 1680 759 363 200 97.8 52.7 
Validation 3  1 6470 3200 1620 733 360 198 98.0 59.6 
  2 6230 3450 1600 756 371 202 92.8 56.5 
  n  6 6 6 6 6 6 6 6 
 Average 6357 3287 1643 746 363 195 99.0 57.5 
 STDEV 229 88.7 38.3 18.4 9.93 9.03 5.75 2.77 
 CV(%) 3.6 2.7 2.3 2.5 2.7 4.6 5.8 4.8 
 %Accuracy 99.3 102.7 102.7 93.3 90.6 97.3 99.0 115.0 
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Table 5.12: Summary of the three validation batches QC results 
Validation 
Batch 
Sample ID LLOQ                  QC - L                   QC - Med                     QC - High              QC - DIL 
Nominal 
Conc. 
50.0 150.0 2560 5120 
11000 
 
(fmol/punch) (fmol/punch) (fmol/punch) (fmol/punch) (fmol/punch) 
  Replicates 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Observed 
Conc. 
Validation 1  1 53.1 143 2150 5080 2570 
  2 50.8 143 2550 5090 2300 
  3 59.5 154 2570 5500 2410 
  4 51.4 157 2550 5250 2310 
  5 58.6 156 2560 5270 2270 
  6 52.1 155 2700 5130 2440 
Validation 2 1 63.7 146 2720 5180   
  2 56.8 159 2650 5290   
  3 65.6 171 2660 5060   
  4 46.2 148 2610 4980   
  5 40.7 173 2690 5510   
  6 62.1 153 2700 5330   
Validation 3 1 52.4 147 2460 4890   
  2 58.4 161 2420 4900   
  3 54.8 152 2470 4970   
  4 57.2 155 2530 5110   
  5 56.5 153 2450 4890   
  6 62.7 149 2450 4940   
 
n  18 18 18 18 6 
 
Average 55.7 154. 2549 5132 2383 
 
STDEV 6.30 8.26 139 194 113 
 
CV(%) 11.3 5.4 5.5 3.8 4.7 
 
%Accuracy 111.4 102.8 99.6 100.2 21.7 
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5.7. Calibration Range 
Results from the validation assays above indicate a valid calibration range of 50–6400 fmol/punch for 
TFV-DP in extracted DBS. The LLOQ was set at the concentration of the lowest validated STD for TFV-
DP, namely 50 fmol/punch. 
 
5.8. Quantification Method 
The results show that the method provides sufficient accuracy and precision over the entire range based 
on analyte/ISTD peak area ratios with quadratic (weighted by 1/x) analysis. 
 
5.9. Stability Assessment 
Various stability experiments were performed to show that all the necessary precautions were taken to 
ensure that the analyte concentrations were not affected by the assay procedure or associated 
conditions. These stability measures are used to dictate how the storage and collection of samples 
should be conducted. The stock solution, working solution, freeze thaw, and benchtop stability of TFV-
DP was not tested, since these stability experiments were previously performed for the indirect method. 
5.9.1. Reinjection Reproducibility 
Reinjection reproducibility is evaluated to determine if an analytical run can be reanalysed by reinjection 
in the case of instrument interruptions. Following the injection of the first validation run (Validation batch 
1), the extracted samples (96-well plate) remained in the autosampler at the method-defined 
temperature (~8˚C) for the following 24 hours and were subsequently reinjected. Summaries of the ~24-
hour reinjected STD and QC results are shown in Tables 5.13 and 5.14, respectively. The extracted 
samples (96-well plate) were also reinjected after being stored at ~4˚C for the following six days, thus 
the samples were reinjected seven days after the extraction was completed. This long storage period 
was chosen due to stringent instrument time constrains, which would not easily allow the reinjection of 
the samples within 24 hours. Therefore, the longer storage period mimics the conditions that would 
most likely be seen in practice. The summaries of the seven-day reinjection results for the STD and QC 
are shown in Tables 5.15 and 5.16, respectively.  
 
Acceptance criteria: The acceptance criteria for this experiment requires that the accuracy remain within 
15% of the nominal value (i.e. %Accuracy should be between 85–115%) and the precision (%CV) 
remain below 15% for all STDs and QCs, except for the LLOQ. The %Accuracy for the LLOQ must 
remain within 20%, whereas the precision must remain below 20%. 
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Discussion:  These requirements were met for the reinjection of the extracted samples after 24 hours; 
however, these requirements were not met with the reinjection of the same samples after 7 days. The 
7-day reinjection failed due to the %Accuracy of the LLOQ, which was not within 20%, Table 5.16. As 
has been mentioned before, there are stringent instrument time constraints and it would be ideal to 
extend the pre-reinjection storage time as far as possible in the case of instrument interruptions. In 
order to do so the samples from the third validation batch (Validation batch 3, day 3) were stored at 4˚C 
after injection and were reinjected after 5 days. The summaries of the STD and QC reinjection results 
of the third validation batch are shown in Tables 5.16 and 5.17, respectively.  
The reinjection of the third validation batch complied with all the acceptance requirements, as can be 
seen in Tables 5.16 and 5.17. Therefore, samples can be stored at 4˚C for up to 5 days if the batch has 
stopped due to instrument interruptions.  
 
Table 5.13: Summary of the results of the STDs reinjected after ~24 hours 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 50.0 59.1 0.57 1.0 118.2 2 of 2 
S7 100 96.2 2.29 2.4 96.2 2 of 2 
S6 200 190 1.09 0.6 94.8 2 of 2 
S5 400 372 4.12 1.1 92.9 2 of 2 
S4 800 736 6.49 0.9 92.0 2 of 2 
S3 1600 1672 23.1 1.4 104.5 2 of 2 
S2 3200 3259 47.3 1.5 101.9 2 of 2 
S1 6400 6364 369 5.8 99.4 2 of 2 
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Table 5.14: Summary of the results of the QCs reinjected after ~24 hours 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
QC LLOQ 50.0 60.0 4.03 6.7 120.0 6 of 6 
QC L 150 152 9.64 6.3 101.6 6 of 6 
QC M 2560 2453 168 6.8 95.8 6 of 6 
QC H 5120 5058 116 2.3 98.8 6 of 6 
 
Table 5.15: Summary of the STDs reinjected after approximately 7 days 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 50.0 59.9 1.13 1.9 119.8 2 of 2 
S7 100 98.2 1.21 1.2 98.2 2 of 2 
S6 200 186 18.5 10.0 92.9 2 of 2 
S5 400 363 11.3 3.1 90.8 2 of 2 
S4 800 736 5.11 0.7 92.0 2 of 2 
S3 1600 1670 17.5 1.0 104.4 2 of 2 
S2 3200 3280 24.5 0.7 102.5 2 of 2 
S1 6400 6355 388 6.1 99.3 2 of 2 
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Table 5.16: Summary of the QCs reinjected after approximately 7 days 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
QC LLOQ 50.0 61.7 2.39 3.9 123.4 6 of 6 
QC L 150 153 9.08 6.0 101.7 6 of 6 
QC M 2560 2451 167 6.8 95.8 6 of 6 
QC H 5120 5070 110 2.2 99.0 6 of 6 
 
 
Table 5.17: Summary of the STDs reinjected after approximately 5 days 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
S8 50.0 55.3 2.55 4.6 110.7 2 of 2 
S7 100 97.2 3.76 3.9 97.2 2 of 2 
S6 200 195 1.28 0.7 97.4 2 of 2 
S5 400 377 10.7 2.8 94.2 2 of 2 
S4 800 779 9.53 1.2 97.3 2 of 2 
S3 1600 1652 62.9 3.8 103.2 2 of 2 
S2 3200 3207 53.8 1.7 100.2 2 of 2 
S1 6400 6389 84.9 1.3 99.8 2 of 2 
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Table 5.18: Summary of the QCs reinjected after approximately 5 days 
Sample ID 
Nominal 
concentration 
(fmol/punch) 
Mean 
Observed 
concentration 
(fmol/punch) 
Standard 
deviation 
CV(%) %Accuracy n 
QC LLOQ 50.0 54.0 7.62 14.1 108.0 6 of 6 
QC L 150 155 4.09 2.6 103.2 6 of 6 
QC M 2560 2503 31.5 1.3 97.8 6 of 6 
QC H 5120 5147 113 2.2 100.5 6 of 6 
 
5.9.2. Autosampler Stability 
In order to assess autosampler stability, the first validation run was reinjected after ~24 hours at the 
designated autosampler temperature, namely ~8˚C. The reinjected high and low QC peak area ratios 
were compared to those obtained during the first injection. This provided an estimation of absolute 
autosampler stability over ~24 hours. A summary of the results of the ~24-hour autosampler stability at 
the high and low concentrations are shown in Tables 5.19 and 5.20, respectively. 
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Table 5.19: Summary of high concentration sample autosampler stability 
High Concentration  
Validation 1, Batch Start Peak area ISTD peak area Ratio 
Injection 1 546000 341000 1.60 
Injection 2 514000 321000 1.60 
Injection 3 552000 318000 1.74 
Injection 4 527000 318000 1.66 
Injection 5 519000 312000 1.66 
Injection 6 522000 323000 1.62 
Average 530000 322167 1.65 
STDEV 15427 9948 0.0518 
CV(%) 2.9 3.1 3.1 
Validation 1 
Reinjection End 
Peak area ISTD peak area Ratio 
Injection 7 539000 343000 1.57 
Injection 8 537000 340000 1.58 
Injection 9 567000 338000 1.68 
Injection 10 556000 340000 1.64 
Injection 11 539000 333000 1.62 
Injection 12 540000 337000 1.60 
Average 546333 338500 1.61 
STDEV 12291 3391 0.0391 
CV(%) 2.2 1.0 2.4 
%Difference after Validation 1 Reinjection -1.9 
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Table 5.20: Summary of low concentration sample autosampler stability 
Low Concentration  
Validation 1, Batch 
Start 
Peak area ISTD peak area Ratio 
Injection 1 14000 364000 0.0385 
Injection 2 12500 325000 0.0385 
Injection 3 13600 327000 0.0416 
Injection 4 13800 323000 0.0427 
Injection 5 13700 322000 0.0425 
Injection 6 13300 317000 0.0420 
Average 13483 329667 0.0410 
STDEV 534 17154 0.00198 
CV(%) 4.0 5.2 4.8 
Validation 1 
Reinjection 
Peak area ISTD peak area Ratio 
Injection 7 13900 365000 0.0381 
Injection 8 13000 346000 0.0376 
Injection 9 15300 351000 0.0436 
Injection 10 14100 329000 0.0429 
Injection 11 12700 340000 0.0374 
Injection 12 14400 338000 0.0426 
Average 13900 344833 0.0403 
STDEV 949 12384 0.00296 
CV(%) 6.8 3.6 7.3 
%Difference after Validation 1 Reinjection -1.5 
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Acceptance criteria: The autosampler stability acceptance criteria require that the %CV and %difference 
not exceed 15%, since this would be an indication of autosampler instability.  
Discussion: The %CV and %difference for the TFV-DP peak area ratios were reported to be within 15%, 
indicating that the ISTD compensates well in the assay and that the samples are stable at the set 
autosampler temperature. Therefore, samples of one batch can be reinjected with samples of a new 
batch, or part of the batch can be reinjected in the case of instrument failure, provided that the storage 
period does not exceed 24 hours. If the pre-reinjection storage period exceeds 24 hours, the samples 
must be placed at 4˚C until they can be reinjected. 
 
5.9.3. Whole Blood Stability 
To allow the adequate collection and handling of patient samples at clinical sites, whole blood stability 
must be determined. Whole blood stability would dictate the amount of time TFV-DP can remain in 
whole blood prior to spotting onto collection paper. Patient samples were used, due to the uncertainty 
of TFV-DP state when it is spiked directly into whole blood (extracellular fluid). The phlebotomist 
collected the whole blood in K3EDTA tubes, which were kept at room temperature until they were 
spotted onto Whatman Protein Saver 903 Cards at the respective timepoints, namely 0 hours, 6 hours, 
24 hours, and 48 hours. The time zero samples were spotted at the clinical site as soon as the whole 
blood collection was completed. The whole blood was kept at room temperature and subsequently 
spotted onto the Whatman Protein Saver 903 Cards at each of the following time points: 6 hours, 24 
hours, and 48 hours. The whole blood of two patients, with varying adherence levels, were used. The 
one patient adhered well to the regimen, whereas the other adhered poorly. This resulted in the one 
patient having high TFV-DP levels, while the other had low TFV-DP levels. Six replicates of each patient 
were analysed, and a summary of the results are shown in Table 5.21. 
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Table 5.21: Summary of whole blood stability result over a period of ~48 hours 
 
Low Concentration (fmol/punch) High concentration (fmol/punch) 
 
Donor 1 Donor 2 
Storage:  
0 hours 
Peak 
Area  
Storage:  
6 hours 
Peak 
Area  
Storage: 
24 hours 
Peak 
Area  
Storage: 
48 
hours 
Peak 
Area  
Storage: 
 0 hours 
Peak 
Area  
Storage:  
6 hours 
Peak 
Area  
Storage:  
24 hours 
 Peak 
Area  
Storage: 
48 
hours 
Peak 
Area  
Sample 1 799 660 644 544 2690 2140 1980 2390 
Sample 2 788 664 620 640 2630 2200 2000 2380 
Sample 3 789 674 659 543 2420 2370 2170 2390 
Sample 4 861 661 634 510 2490 2380 2100 2400 
Sample 5 817 667 671 593 2810 2410 2230 2310 
Sample 6 883 726 626 538 2590 2280 2110 2370 
Average 823 675 642 561 2605 2297 2098 2373 
STDEV 40.1 25.3 19.7 46.9 140 109 96.2 32.7 
CV(%) 4.9 3.8 3.1 8.4 5.4 4.7 4.6 1.4 
%Difference   -17.9 -21.9 -31.8   -11.8 -19.4 -8.9 
*The percentage difference for each time point is calculated using T0 (0 hours) and the respective Time point. 
 
Acceptance criteria: The acceptance criteria for the whole blood stability assay requires the %Difference 
remain below 15%, otherwise it is an indication of whole blood instability.  
Discussion:  The %Difference for all the low concentration time points failed to comply with the 
requirements, whereas only one of the high concentration timepoints failed, as can be seen in Table 
5.21. Therefore, TFV-DP is not stable in whole blood and must be spotted onto the Whatman Protein 
Saver 903 Cards immediately after the blood has been collected. 
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5.10. Specificity 
The very high specificity of the LC-MS/MS assay procedure prevents the detection of any compounds 
that do not possess the capability to produce the specific parent ion followed by formation of the specific 
product ion produced and monitored in the mass spectrometer. A representative chromatogram of the 
first STD (6400 fmol/punch) is shown in Figure 5.4. 
 
Figure 5.4: Representative chromatogram of STD 1: TFV-DP and ISTD. 
 
5.11. Carry-Over 
A double blank sample (without analyte and ISTD) was positioned in the injection sequence immediately 
after the highest STD to assess possible carry-over effects.  A chromatogram of a double blank sample 
is presented in Figure 5.5. 
A blank sample (without analyte) was also included to determine the possible contamination of the 
analyte by the ISTD without an additional carry-over effect. A chromatogram of a blank sample is 
presented in Figure 5.6. 
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Figure 5.5: Chromatogram of an extracted double blank DBS sample. 
 
 
Figure 5.6: Chromatogram of an extracted blank DBS sample. 
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Acceptance criteria:   
Double blank assessing carry-over: A peak that is observed for the analyte should not be > 20% of the 
area of the peak obtained at the LLOQ. A peak that is observed for the ISTD should not be > 5% of the 
peak observed for the ISTD at the working concentration. 
Blank assessing contribution of ISTD to analyte peak area: A peak that is observed for the analyte when 
ISTD is present at the working concentration should not be > 20% of the area of the peak obtained at 
the LLOQ. 
Discussion: No analyte peaks were seen at the retention time and mass transition of TFV-DP in the 
double blank and blank samples. 
 
5.12. Sensitivity 
The LLOQ of this method is 50 fmol/punch, Figure 5.7. Six different lots of matrix were prepared at the 
LLOQ concentration and extracted, to determine the average signal-to-noise ratio at LLOQ, Figures 
5.8–5.13.  
 
Figure 5.7: Representative chromatogram of a TFV-DP LLOQ sample. 
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Figure 5.8: Raw chromatogram: The 1st sample spiked at LLOQ. 
 
 
Figure 5.9: Raw chromatogram: The 2nd sample spiked at LLOQ. 
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Figure 5.10: Raw chromatogram: The 3rd sample spiked at LLOQ. 
 
 
Figure 5.11: Raw chromatogram: The 4th sample spiked at LLOQ. 
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Figure 5.12: Raw chromatogram: The 5th sample spiked at LLOQ. 
 
 
Figure 5.13: Raw chromatogram: The 6th sample spiked at LLOQ. 
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Acceptance criteria: The mean analyte signal/noise response at LLOQ should be at least more than 
five times the response compared to blank response at the retention time of interest. 
Discussion: The raw LLOQ sample chromatograms presented acceptable intensities for the analyte 
with an average signal-to-noise ratio of 39.7 (n=6), calculated from six replicates of LLOQ samples 
prepared from DBS obtained from six different sources. 
 
5.13. Recovery 
The extraction recovery pertains to the extraction efficiency of the analytical process within the limits of 
variability.  It is determined by comparing the analytical response of blank matrix, spiked with the analyte 
and extracted, with the response of the blank matrix, which is first extracted and then spiked with analyte 
(theoretical, represents 100% recovery). No recovery of the ISTD is calculated. 
 
a. Extracted (test) samples:  A minimum of 6 QCs at each concentration level in 6 different lots of 
matrix (low, medium and high) are extracted as per the analytical method describe in Chapter 4. 
b. Theoretical samples: Samples are spiked at each concentration level (relative to the final 
concentration of the corresponding extracted QC level) in six-fold using extracted blank matrix from 6 
different lots of matrix. 
The analyte peak areas found after extraction are compared to the theoretical peak area expressed as 
a percentage recovery. A summary of the results is shown in Table 5.22. 
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Table 5.22: Summary of the recovery results for TFV-DP 
 
High Concentration  
(5120 fmol/punch) 
Medium Concentration 
 (2560 fmol/punch) 
Low Concentration 
 (150 fmol/punch) 
Pre-
extraction 
spiked:  
Post- 
extraction 
spiked:  
Pre-
extraction 
spiked: 
Post-
extraction 
spiked:  
Pre-
extraction 
spiked: 
Post 
extraction 
spiked:  
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 810000 1110000 349000 520000 19900 27900 
Sample 2 793000 1090000 348000 489000 19300 27500 
Sample 3 841000 985000 363000 513000 19100 27300 
Sample 4 920000 1380000 429000 624000 24500 36100 
Sample 5 779000 1080000 372000 519000 19700 29700 
Sample 6 960000 1340000 465000 610000 23600 32700 
Average 850500 1164167 387667 545833 21017 30200 
STDEV 73443 158190 48190 56432 2384 3530 
CV(%) 8.6 13.6 12.4 10.3 11.3 11.7 
%Recovery   73.1   71.0   69.6 
     Average %Recovery 71.2 
 
   
Average CV(%) 2.4 
 
Acceptance Criteria:  The mean recovery of a bioanalytical method should be consistent and the 
precision of the measured recovery expressed as CV(%) should not exceed 15% for any particular 
concentration of the analyte at which it is determined.  Recovery reproducibility between concentration 
levels should not be > 15%. 
Discussion: The mean recovery of TFV-DP from six different lots of DBS over the calibration range is  
71.2% with a CV(%) of 2.4% and is within acceptable limits.   
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5.14. Matrix Effects 
In biological analyses, matrix refers to the endogenous (or non-endogenous) components of a sample 
other than the analyte being studied. Matrix effects are of particular importance in LC-MS/MS analyses, 
and may only become evident once unknown clinical samples are analysed. The presence of 
background matrix components may have an effect on analyte and ISTD ionization. Having an 
appropriate ISTD which adequately follows the analyte, compensates for matrix effects. Appropriate 
steps should be taken to minimize the influence of matrix components. The Matuszewski method 
attempts to quantify the effect across the calibration range of the assay using different matrix sources 
99,100,115. 
A minimum of 6 different blank sources of the appropriate biological matrix were extracted (without 
ISTD).  Each individual matrix sample was spiked at low, medium and high concentration levels (taking 
into account any calculations for dilutions in the analytical method), and at one concentration of the 
ISTD. The results are presented in Table 5.23 and the overall CV(%)’s of the regression slopes 
calculated is shown in Table 5.24. 
 
Table 5.23: TFV-DP and ISTD peak areas 
 High Concentration  Medium Concentration  Low Concentration  
 
Analyte Peak 
Area  
ISTD Peak 
Area  
Analyte 
Peak Area  
ISTD Peak 
Area  
Analyte 
Peak Area  
ISTD Peak 
Area  
Sample 1 1110000 707000 520000 724000 27900 711000 
Sample 2 1090000 711000 489000 666000 27500 619000 
Sample 3 985000 649000 513000 669000 27300 713000 
Sample 4 1380000 914000 624000 831000 36100 905000 
Sample 5 1080000 712000 519000 692000 29700 735000 
Sample 6 1340000 852000 610000 849000 32700 873000 
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Table 5.24: Regression results from different matrices 
 
High 
concentration 
Medium 
concentration  
Low 
Concentration 
Area Ratio  
v Conc.  
Regression 
Slope 
(5120 fmol/punch) (2560 fmol/punch) (150 fmol/punch) 
Peak Area Ratio Peak Area Ratio Peak Area Ratio 
Sample 1 1.57 0.72 0.0392 0.000308 
Sample 2 1.53 0.73 0.0444 0.000300 
Sample 3 1.52 0.77 0.0383 0.000298 
Sample 4 1.51 0.75 0.0399 0.000296 
Sample 5 1.52 0.75 0.0404 0.000297 
Sample 6 1.57 0.72 0.0375 0.000309 
Average 1.54 0.74 0.0400 0.000301 
STDEV 0.0279 0.0195 0.00244 0.00000591 
CV(%) 1.8 2.6 6.1 2.0 
 
 
Acceptance criteria:  The peak area ratios of the analyte/ISTD for each level in each matrix source are 
used to generate regressions for each individual matrix. From the generated regressions the calculated 
slope variability (CV(%)) for the six different matrix sources should not exceed 5%. 
Discussion: The slope variability (CV(%)) for six different K3EDTA DBS samples is 2.0% for TFV-DP, 
which indicates that matrix effects do not adversely influence the precision of the assay. 
 
5.15. Process Efficiency 
Process efficiency is a comparison between the instrument response from ‘extracted samples’ and the 
instrument response obtained from ‘unextracted neat samples’ (analyte spiked into injection solvent 
without any matrix). Process efficiency assesses the combined effect of both extraction recovery and 
matrix on analyte quantitation. 
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The pre-extraction spiked samples are prepared in six different lots of matrix at the low, medium and 
high QC levels and extracted as per the method described in Chapter 4. The ISTD is spiked at the 
working concentration of the method.   
The neat, un-extracted samples are prepared in triplicate in the injection solution (water) at low, 
medium, and high QC levels (considering any calculations for dilutions in the analytical method). The 
ISTD is spiked into the samples at the working concentration of the method. A volume of 150 µl of each 
sample is subsequently added to a 96-well plate. 
The analyte peak areas observed after extraction are compared to the peak areas of the neat samples 
and expressed as percentage process efficiency. The results of the process efficiency assessment are 
summarised in Tables 5.25. 
 
Table 5.25: Process efficiency for the extraction of TFV-DP from DBS 
 
High Concentration  
(5120 fmol/punch) 
Medium Concentration 
(2560 fmol/punch) 
Low Concentration 
(150 fmol/punch) 
Extracted 
solution:  
Neat 
solution:  
Extracted 
solution: 
Neat 
solution: 
Extracted 
solution: 
Neat 
solution: 
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 810000 1480000 349000 771000 19900 42500 
Sample 2 793000 1530000 348000 830000 19300 42300 
Sample 3 841000 1630000 363000 824000 19100 43800 
Sample 4 920000   429000   24500   
Sample 5 779000   372000   19700   
Sample 6 960000   465000   23600   
Average 850500 1546667 387667 808333 21017 42867 
STDEV 73443 76376 48190 32470 2384 814 
CV(%) 8.6 4.9 12.4 4.0 11.3 1.9 
%Recovery   55.0   48.0   49.0 
 
   
Average %Process 
efficiency 
50.7 
    Average CV(%) 7.5 
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Acceptance criteria: Process efficiency represents the combined effect of matrix presence and 
extraction efficiency on the analyte. The mean process efficiency of a quantitative drug assay method 
should be consistent. The precision of the measured process efficiency, expressed as CV(%), should 
not exceed 15% for any particular concentration of the analyte at which it is determined.  Process 
efficiency reproducibility between concentration levels should not be > 15%. 
Discussion: The mean process efficiency of TFV-DP from six different lots of DBS over the calibration 
range is 50.7% with a CV(%) of 7.5% and is within acceptable limits.   
 
5.16. Dilutions 
To determine if samples originally reported as above the upper limit of quantitation (ALQ) of the 
standard curve may be diluted to within the calibration range with accuracy and precision, six extra high 
QC Dilute samples were prepared at a concentration more than twice the ULOQ (11000 fmol/punch) 
for TFV-DP. These were subsequently diluted 1:4 with blank extracted samples. The concentration was 
determined and compared with the nominal concentration to determine the percentage accuracy. The 
results are shown in Table 5.26.  
 
Table 5.26: Summary of the dilution sample results for TFV-DP 
 1:4 Dilution 
 Nominal concentration 
(fmol/punch) 
Calculated concentration 
(fmol/punch)  
Sample 1 2200 2570 
Sample 2  2300 
Sample 3  2410 
Sample 4  2310 
Sample 5  2270 
Sample 6  2440 
Average 2200 2383 
STDEV  113 
CV(%)  4.7 
%Accuracy  108.3 
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Acceptance criteria:  The final mean calculated concentration (incorporating the dilution factor) is 
determined from the calibration curve and compared to the nominal concentration. The accuracy of the 
extracted samples is required to be within 15% (i.e. %Accuracy should be between 85–115%) and the 
precision is required to be less than 15% (i.e. CV(%) should be less than 15%). 
Discussion: The resulted precision and accuracy fall within the accepted limits and, therefore, 
concentration reported above the upper limit of the validated calibration curve may be diluted 1:4 and 
repeated.  
 
5.17. Anticoagulant Matrix Effects 
K3EDTA was selected as the analytical methods anticoagulant of choice; however, there is a possibility 
that samples may be collected at the clinical site using other anticoagulant tubes. Therefore, the matrix 
anticoagulant effects of K2EDTA also had to be determined and compared to those of the K3EDTA 
samples. This would thus determine if samples that have been collected using an alternative 
anticoagulant could be analysed.  
QC high, medium, and low samples were prepared to determine the effect of an alternative 
anticoagulant on the analytical method. Six replicates from different blank matrix sources were analysed 
at each concentration level. The samples were subsequently extracted and quantified and the result 
are shown in Table 5.27. 
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Table 5.27: Summary of the effect of K2EDTA on the assay 
 
High Concentration  Medium Concentration  Low Concentration  
K3EDTA K2EDTA K3EDTA K2EDTA K3EDTA K2EDTA 
Peak Area Peak Area Peak Area Peak Area Peak Area Peak Area 
Sample 1 4890 5000 2460 2440 147 160 
Sample 2 4900 5180 2420 2440 161 148 
Sample 3 4970 4940 2470 2440 152 166 
Sample 4 5110 4860 2530 2270 155 152 
Sample 5 4890 5130 2450 2470 153 156 
Sample 6 4940 5100 2450 2500 149 155 
Average 4950 5035 2463 2426 152 156 
STDEV 84.6 123 36.7 80.5 4.92 6.27 
CV(%) 1.7 2.4 1.5 3.3 3.2 4.0 
%Difference   1.7   -1.5   2.2 
 
Acceptance criteria:  The accuracy of the extracted K2EDTA samples is required to be less than 15% 
(i.e. %Accuracy should be between 85–115%) and the precision is required to be less than 15% (i.e. 
CV(%) should be less than 15%). 
Discussion: The resulted precision and accuracy fall within the accepted limits. Therefore, the assay 
can be used to analyse samples that have mistakenly been collected with K2EDTA as anticoagulant. 
 
5.18. Direct vs Indirect Method 
To determine the correlation between the previous indirect and the newly developed direct method, a 
set of 30 patient samples were analysed using both methods. The samples used formed part of the 
Pluspills study. Approval to use the DBS samples was obtained from the Human Research Ethics 
Committee of the Faculty of Health Sciences, University of Cape Town (Reference number: 260/2014).  
While working with the patient samples, standard good laboratory practises (GLP) were followed as 
outlined in the laboratory’s standard operating procedures (SOP). This requires lab personnel to wear 
adequate  personal protection when generating or working with waste. The required personal protection 
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includes a laboratory coat, disposable latex gloves and eye protection. All waste generated during the 
analytical process was discarded in the appropriate demarcated receptacles. Medical waste was 
discarded in a clearly demarcated red bin, which contained medical waste without any sharps or 
glassware. The content of the red bins are incinerated after collection. Sharps and glassware were 
discarded in separate yellow bins (sharps bin) in order to prevent the puncture of the red bin bags, 
which may lead to medical waste leakage. Therefore, adequate measures were taken to ensure that 
medical waste was handled and discarded safely.  
The same samples were analysed with the two different methods. The Pearson’s correlation coefficient 
was calculated as an indication of the degree of correlation between the current indirect method and 
the developed direct method. A regression analysis was also completed as an indication of the 
correlation of the two methods. The formula for the Pearson’s correlation coefficient is shown below: 
 
𝑟 =
𝑛(∑ 𝑥𝑦) − (∑ 𝑥)(∑ 𝑦)
√[𝑛 ∑ 𝑥2 − (∑ 𝑥)2][𝑛 ∑ 𝑦2 − (∑ 𝑦)2]
 
 
The same samples were analysed using both methods and the results of the two methods are 
summarised in Table 5.29. A scatterplot presenting the data is shown in Figure 5.14, which gives a 
visual representation of the data.  
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Table 5.28: Summary of the results obtained from the two analytical methods, namely UCT direct and 
the UCT indirect 
 
UCT direct method (fmol/punch) Indirect method (fmol/punch) 
 
 
TPC0029 2520 1743 
TPC0030 2460 1389 
TPC0032 899 714 
TPC0034 2760 2018 
TPC0036 1560 1155 
TPC0038 2270 1608 
TPC0040 1360 1173 
TPC0042 501 380 
TPC0044 1930 946 
TPC0046 1400 1006 
TPC0048 365 357 
TPC0050 1900 1003 
TPC0052 1970 1192 
TPC0054 3370 1813 
TPC0056 1290 801 
TPC0058 1900 1305 
TPC0060 2400 1168 
TPC0062 889 553 
TPC0064 1160 755 
TPC0066 2100 1073 
TPC0068 977 632 
TPC0070 1960 1152 
TPC0072 874 833 
TPC0074 2730 1503 
TPC0075 2120 1170 
TPC0076 3820 2523 
TPC0077 2320 1374 
TPC0078 2160 1411 
TPC0079 1320 833 
TPC0080 2050 1477 
Average 1845 1169 
STDEV 8045 480 
CV(%) 43.6 41.0 
%Difference   -36.6 
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Figure 5.14: A scatterplot with a trendline of the relationship of the results obtained using the developed 
direct method and the indirect method used by UCT. The r2 value is 0.8704. 
 
As can be seen in Figure 5.14, a linear relationship can be observed between the results of the direct 
and indirect methods, and this is backed up by the coefficient of determination (r2) that approaches one. 
The Pearson’s correlation coefficient was 0.933, which indicates a strong positive correlation between 
the data obtained by the developed direct and indirect methods. The correlation was statistically 
significant (P≤0.0001). A regression analysis was also completed, and the r2 value was 0.870, which 
also implies a strong correlation.   
On average, the results obtained using the direct method were 36.6 % higher than those obtained using 
the indirect method. This may be as a result of the indirect method that takes the reference standard 
purity indirectly into account, whereas the direct method assumes the purity of the reference standard 
is exactly as stated on the certificate of analysis. However, the correlation from relatively low to high 
concentrations is strong and therefore a correction factor could be used to adjust the data for adherence 
studies. 
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Chapter 6: Conclusion 
According to the data generated in the current study it was evident that the developed method met the 
FDA and EMA requirements for a bioanalytical assay. The aim of the study was to develop a method 
that could be used as an alternative to the existing TFV-DP indirect method. The existing indirect 
method used a technique which separates the parent drug from the metabolite and then back-converted 
all metabolites to the parent drug before analysing the samples on LC-MS/MS. The developed direct 
method avoided these laborious sample preparation steps, which ultimately reduced the time taken for 
each assay and the associated cost of the consumables. Therefore, the development and validation of 
the bioanalytical method made it possible for researchers, with limited funding, to accurately determine 
the TFV-DP levels of patients. The validation experiments were meant to, not only determine the 
suitability of the method for its intended use, but also to ensure the reproducibility, robustness, and 
reliability of the method. Therefore, the method could be an adequate alternative to the indirect method 
currently used. However, when compared to the current method the results of the developed method 
were higher than those obtained using the current indirect method. Therefore, therefore a correction 
factor could be used to adjust the data for adherence studies. 
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